EP2142527A1 - Pyridine and pyrimidine derivatives as mglur2 antagonists - Google Patents

Pyridine and pyrimidine derivatives as mglur2 antagonists

Info

Publication number
EP2142527A1
EP2142527A1 EP08718155A EP08718155A EP2142527A1 EP 2142527 A1 EP2142527 A1 EP 2142527A1 EP 08718155 A EP08718155 A EP 08718155A EP 08718155 A EP08718155 A EP 08718155A EP 2142527 A1 EP2142527 A1 EP 2142527A1
Authority
EP
European Patent Office
Prior art keywords
trifluoromethyl
pyridin
pyrimidin
formula
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP08718155A
Other languages
German (de)
French (fr)
Other versions
EP2142527B1 (en
Inventor
Silvia Gatti Mcarthur
Juergen Wichmann
Thomas Woltering
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39457413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2142527(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Priority to EP08718155A priority Critical patent/EP2142527B1/en
Publication of EP2142527A1 publication Critical patent/EP2142527A1/en
Application granted granted Critical
Publication of EP2142527B1 publication Critical patent/EP2142527B1/en
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to compounds of formula (I), a process for the manufacture thereof, their use for the preparation of medicaments for treating CNS disorders and pharmaceutical compositions containing them.
  • either one of X or Y is N and the other is CH, or both X and Y are N;
  • A is aryl or 5 or 6 membered heteroaryl each of which is optionally substituted by C 1-
  • B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituents are selected from the group consisting of: halo, nitro,
  • Ci-6-alkyl optionally substituted by hydroxy, NR a R b , wherein R a and R b are independently H, C 1-6 -alkyl or -(CO)-C 1-6 - alkyl,
  • Ci-6-alkyl optionally substituted by hydroxy, Ci- 6 -haloalkyl,
  • -(CO)Ci- 6 -alkyl optionally substituted by Ci- 6 -alkoxy, -(CH 2 CH 2 O) n CHR 6 , wherein R e is H or CH 2 OH and n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, -(CH 2 ) m -aryl, wherein m is 1 or 2 and the aryl is optionally substituted by halo or Ci- 6 -alkoxy, -(CH 2 ) p -C 3 - 6 -cycloalkyl, wherein p is 0 or 1, 5 or 6-membered heterocycloalkyl,
  • R and R g together with the nitrogen atom to which they are attached form a 4, 5 or 6 membered heterocycloalkyl ring optionally containing a further heteroatom selected from nitrogen, oxygen, sulphur or a SO 2 group, wherein said 4, 5 or 6 membered heterocycloalkyl ring is optionally substituted by a substituent selected from the group consisting of: hydroxy, Ci- 6 -alkyl, Ci- 6 -alkoxy which is optionally substituted by hydroxy, and 5 or 6 membered heteroaryloxy,
  • R h and R 1 are independently H, C 1-6 -alkyl, -(CO)O- Ci- 6 -alkyl, or R and R 1 together with the nitrogen atom to which they are attached form a 4, 5 or 6 membered heterocycloalkyl ring optionally containing a further heteroatom selected from nitrogen, oxygen or sulphur, wherein said 4, 5 or 6 membered heterocycloalkyl ring is optionally substituted by Ci- 6 -alkyl, R 1 is H, halogen, Ci- 6 -alkyl optionally substituted by hydroxy, Ci- 6 -alkoxy, C 1 ⁇ - haloalkyl, C 3 - 6 -cycloalkyl; R 2 is selected from the group consisting of: cyano, halogen, Ci- 6 -haloalkyl, Ci- 6 -alkoxy, Ci- 6 -haloalkoxy, Ci- 6 -alkyl and C 3 -
  • the transmission of stimuli takes place by the interaction of a neurotransmitter, which is sent out by a neuron, with a neuroreceptor.
  • L-glutamic acid the most commonly occurring neurotransmitter in the CNS, plays a critical role in a large number of physiological processes.
  • the glutamate-dependent stimulus receptors are divided into two main groups.
  • the first main group forms ligand- controlled ion channels.
  • the metabotropic glutamate receptors (mGluR) form the second main group and, furthermore, belong to the family of G-protein-coupled receptors.
  • these eight receptors can be sub-divided into three sub-groups: mGluRl and mGluR5 belong to group I, mGluR2 and mGluR3 belong to group II and mGluR4, mGluR ⁇ , mGluR7 and mGluR8 belong to group III.
  • Ligands of metabotropic glutamate receptors belonging to the group II can be used for the treatment or prevention of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits.
  • treatable indications in this connection are restricted brain function caused by bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest and hypoglycaemia.
  • Further treatable indications are chronic and acute pain, Huntington's chorea, amyotrophic lateral sclerosis (ALS), dementia caused by AIDS, eye injuries, retinopathy, idiopathic parkinsonism or parkinsonism caused by medicaments as well as conditions which lead to glutamate-deficiency functions, such as e.g.
  • Objects of the present invention are compounds of formula (I) and their pharmaceutically acceptable salts per se and as pharmaceutically active substances, their manufacture, medicaments based on a compound in accordance with the invention and their production, as well as the use of the compounds in accordance with the invention in the control or prevention of illnesses of the aforementioned kind, and, respectively, for the production of corresponding medicaments.
  • the compounds of formula (I) can also be used in form of their prodrugs.
  • examples are esters, N-oxides, phosphate esters, glycoamide esters, glyceride conjugates and the like.
  • the prodrugs may add to the value of the present compounds advantages in absorption, pharmacokinetics in distribution and transport to the brain.
  • alkyl denotes straight- chain or branched saturated hydrocarbon residues with 1 to 6 carbon atoms (Ci- 6 -alkyl), preferably with 1 to 4 carbon atoms, such as methyl, ethyl, n-propyl, i-propyl, i-butyl, t- butyl, as well as those groups which are illustrated with the exemplified compounds of the invention hereinafter.
  • Ci- 6 -haloalkyl denotes a Ci- 6 -alkyl group as defined hereinabove, which is substituted by one or more halogen atom(s), in particular Cl, F or I, preferably three Cl or two or three F, i.e. CCI 3 , CHF 2 and CF 3 as well as those groups which are specifically illustrated with the exemplified compounds of the invention hereinafter.
  • Ci- 6 -alkoxy denotes a Ci- 6 -alkyl residue in the sense of the foregoing definition bound via an oxygen atom.
  • Examples of "Ci- 6 -alkoxy” residues include methoxy, ethoxy, isopropoxy, as well as those groups which are illustrated with the exemplified compounds of the invention hereinafter.
  • Ci- 6 -haloalkoxy denotes a Ci- 6 -alkoxy group as defined hereinabove, which is substituted by one or more halogen atom(s), in particular Cl, F or I, preferably three Cl or two or three F, i.e. OCHF 2 and OCF 3 , OCH 2 CHF 2 , OCH 2 CF 3 as well as those groups which are specifically illustrated with the exemplified compounds of the invention hereinafter.
  • aryl denotes a monovalent cyclic aromatic hydrocarbon radical, for example phenyl, naphthyl, biphenyl or indanyl.
  • heteroaryl or 5 or 6-membered heteroaryl or heteroaryl having from 5 to 12 ring atoms refers to an aromatic having 5 to 6 or 5 to 12 ring atoms and containing one or more, in particular, one, two, three, four or five and preferably one, two or three heteroatoms selected from nitrogen, oxygen or sulphur.
  • heteroaryl groups include thiophenyl, imidazolyl, oxadiazolyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl or pyridazinyl, and in particular, [1,2,4] oxadiazolyl, pyridin-2-yl, pyridin-3-yl, pyridine-4-yl, pyrimidin-5-yl, thiazol-2-yl and thiophen-2-yl as well as those groups which are illustrated with the exemplified compounds of the invention hereinafter.
  • heteroaryloxy denotes a heteroaryl group, including 5 or 6-membered heteroaryl or heteroaryl having from 5 to 12 ring atoms as defined hereinabove, which is connected via an oxygen atom.
  • halogen embraces fluorine (F), chlorine (Cl), bromine (Br) and iodine (I).
  • C 3 - 6 -cycloalkyl or Cs- ⁇ -cycloalkyl means a cycloalkyl group containing 3 to 6 or 5 to 8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl as those groups which are illustrated with the exemplified compounds of the invention hereinafter.
  • 5 or 6-membered or 5 to 12-membered heterocycloalkyl denotes a heterocyclic ring having 5 or 6 or 5 to 12 ring members comprising at least two carbon atoms as ring member and 1, 2 or 3 additional heteroatom(s) ring members selected from N, O or S, the remaining ring members being carbon atoms.
  • heterocycloalkyl rings examples include but are not limited to lff-tetrazole; 2ff-tetrazole; 1,2,3- and 1,24-triazole; imidazole; pyrrole; 1,2,3-, 1,3,4- or 1,2,5- thiadiazine; 1,4-oxazine; 1,2- or 1,4-thiazine; 4-morpholinyl; 1 -pyrrolidinyl; 1 -piperazinyl, preferably 4-morpholinyl; 1 -pyrrolidinyl or 1 -piperazinyl as well as those groups which are illustrated with the exemplified compounds of the invention hereinafter.
  • Substituents for such 5 or 6 membered heterocyclic ring include but are not limited to halo, amino, nitro, cyano, hydroxy, Ci-6-alkyl optionally substituted by hydroxy, Ci-6-alkoxy, Ci-6-alkenyl, C 3 - ⁇ - cycloalkyl, or CF 3 , and preferably Ci-6-alkyl or CF 3 as well as those groups which are illustrated with the exemplified compounds of the invention hereinafter.
  • optionally substituted means that the chemical group to which it refers can be substituted by one or more of the substituents recited in this connection, for example by one, two, three, four, five, six, seven, eight, nine or ten substituents, depending on the valence and available positions of said chemical group.
  • pharmaceutically acceptable addition salt refers to any salt derived from an inorganic or organic acid or base.
  • the compounds of formula (I) and their pharmaceutically acceptable salts are metabotropic glutamate receptor antagonists and can be used for the treatment or prevention of acute and/or chronic neurological disorders, such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits.
  • Other treatable indications are restricted brain function caused by bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest and hypoglycaemia.
  • Further treatable indications are acute and chronic pain, Huntington's chorea, ALS, dementia caused by AIDS, eye injuries, retinopathy, idiopathic parkinsonism or parkinsonism caused by medicaments as well as conditions which lead to glutamate-deficient functions, such as e.g. muscle spasms, convulsions, migraine, urinary incontinence, nicotine addiction, psychoses, opiate addiction, anxiety, vomiting, dyskinesia, depression, colon cancer, sleep disorders, disorders of circadian rhythms and glioma.
  • B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituents are selected from the group consisting of: NR a R b , wherein R a and R b are independently H,
  • R c and R d are independently: H,
  • R 1 is Ci- 6 -alkyl or Ci- 6 -haloalkyl;
  • R 2 is 5 or 6 membered heteroaryl optionally substituted by one, two or three substituents selected from the group consisting of: halogen and Ci- 6 -haloalkyl; as well as pharmaceutically acceptable salts thereof. Also encompassed by the compounds of formula (I) according to the invention are the compounds of formula (Ia):
  • B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituent is NR a R b , wherein R a and R b are both H, for example the following compounds:
  • B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituent is NR a R b , wherein R a and R b are H and -(SO 2 )-NR c R d , wherein R c and R d are independently H, Ci- 6 -alkyl, or -(CO)Ci- 6 -alkyl, for example the following compounds:
  • B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituent is NR a R b , wherein R a and R b are both H, for example the following compound: 4- [4-Trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl] - [2,3']bipyridinyl-6'-ylamine.
  • B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituent is NR a R b , wherein R a and R b are H and -(SO 2 )-NR c R d , wherein R c and R d are independently H, Ci- 6 -alkyl, or -(CO)Ci- 6 -alkyl, for example the following compounds:
  • the compounds of formula (Ic) B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituent is NR a R b , wherein R a and R b are H and -(SO 2 )-NR c R d , wherein R c and R d are independently H, Ci- 6 -alkyl, or -(CO)Ci- 6 -alkyl, for example the following compounds:
  • B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituent is NR a R b , wherein R a and R b are both H, for example the following compounds:
  • B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituent is NR a R b , wherein R a and R b are H and -(SO 2 )-NR c R d , wherein R c and R d are independently H, Ci- 6 -alkyl, or -(CO)Ci- 6 -alkyl, for example the following compounds:
  • the invention also encompasses processes for the preparation of the compounds of the invention.
  • the compounds of the invention can be prepared by a process comprising the steps of reacting a compound of formula (X):
  • the catalyst can be tetrakis(triphenylphosphine) -palladium.
  • the reaction can be performed in an organic solvent, e.g. dioxane.
  • the starting products, intermediates products and reagents for this process are either commercially available or can be prepared as described in the examples hereinafter.
  • the compounds of the invention can also be prepared by a process comprising the steps of reacting a compound of formula (XXVI):
  • the starting products, intermediates products and reagents for this process are either commercially available or can be prepared as described in the examples hereinafter.
  • the compounds of formula (I) and pharmaceutically acceptable salts thereof can be used as medicaments, e.g. in the form of pharmaceutical preparations.
  • the pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions.
  • the administration can also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.
  • the compounds of formula (I) and pharmaceutically acceptable salts thereof can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations.
  • Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragees and hard gelatine capsules.
  • Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like; depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules.
  • Suitable carriers for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar, glucose and the like.
  • Adjuvants such as alcohols, polyols, glycerol, vegetable oils and the like, can be used for aqueous injection solutions of water-soluble salts of compounds of formula (I), but as a rule are not necessary.
  • Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
  • the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
  • medicaments containing a compound of formula (I) or a pharmaceutically acceptable salt thereof and a therapeutically inert excipient are also an object of the present invention, as is a process for the production of such medicaments which comprises bringing one or more compounds of formula (I) or pharmaceutically acceptable salts thereof and, if desired, one or more other therapeutically valuable substances into a galenical dosage form together with one or more therapeutically inert carriers.
  • the dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case.
  • the effective dosage for oral or parenteral administration is between 0.01-20 mg/kg/day, with a dosage of 0.1-10 mg/ kg/ day being preferred for all of the indications described.
  • the present invention relates also to the use of compounds of formula (I) and of pharmaceutically acceptable salts thereof for the production of medicaments, especially for the control or prevention of acute and/or chronic neurological disorders of the aforementioned kind.
  • the compounds of the present invention are group II mGlu receptor antagonists.
  • the compounds show activities, as measured in the assay described below, of 0.250 ⁇ M or less, typically 0.100 ⁇ M or less, and ideally of 0.010 ⁇ M or less.
  • activities as measured in the assay described below, of 0.250 ⁇ M or less, typically 0.100 ⁇ M or less, and ideally of 0.010 ⁇ M or less.
  • Ki values of some preferred compounds. Ex. No. 1 2 3 4 5 8 9
  • cDNA encoding the rat mGlu2 receptor protein in pBluescript II was subcloned into the eukaryotic expression vector pcDNA I-amp from Invitrogen Ltd (Paisley, UK).
  • This vector construct (pcDlmGR2) was co-transfected with a psvNeo plasmid encoding the gene for neomycin resistance, into CHO cells by a modified calcium phosphate method described by Chen & Okayama (1988).
  • the cells were maintained in Dulbecco's Modified Eagle medium with reduced L-glutamine ( 1 mM final concentration), 36mg/L L-Proline and 10 % dialysed foetal calf serum from Gibco-Invitrogen; the medium was supplemented with 500 microM ⁇ -methyl-4-carboxyphenylglycine (MCPG) . Selection was made in the presence of G-418 (300 ug/ml final concentration).
  • MCPG microM ⁇ -methyl-4-carboxyphenylglycine
  • Clones were identified by reverse transcription of 5 ⁇ g total RNA, followed by PCR using mGlu2 receptor specific primers 5'-atcactgcttgggtttctggcactg-3' and 5'- agcatcactgtgggtggcataggagc-3' in 60 mM Tris HCl (pH 10), 15 mM (NH4) 2 SO 4 , 2 mM MgCl 2 , 25 units/ml Taq Polymerase with 30 cycles annealing at 60 0 C for 1 min., extention at 72 0 C for 30 s, and 1 min. 95 0 C denaturation.
  • Membrane preparation Cells cultured as above, were harvested and washed three times with cold PBS and frozen at -80 0 C.
  • the pellet was resuspended in cold 20 mM HEPES-NaOH buffer containing 10 mM EDTA (pH 7.4), and homogenised with a polytron (Kinematica, AG, Littau, Switzerland) for 10 s at 10 000 rpm. After centrifugation for 30 min. at 4 0 C, the pellet was washed once with cold 20 mM HEPES-NaOH buffer containing 0.1 mM EDTA, (pH 7.4). After a second centrifugation for 30 min.
  • the membranes were resuspended in cold 5OmM Tris-HCl buffer containing 2 mM MgCl 2 (pH 7.4) (binding buffer). The final concentration of the membranes in the assays was 25 ⁇ g protein/ml. Inhibition experiments were performed with membranes incubated with 10 nM [ 3 H]-LY354740 at room temperature, for 1 hour, in presence of various concentrations of the compound to be tested. Following the incubations, membranes were filtered onto Whatmann GF/B glass fiber filters or onto GF/B Unifilter plates and washed 5 times with cold binding buffer.
  • Non specific binding was measured in the presence of 10 ⁇ M (2S,2'_R,3'i?)-2-(2'3'- Dicarboxycyclopropyl) glycine (DCG IV from Tocris, Ellisville, MO USA).
  • DCG IV from Tocris, Ellisville, MO USA
  • the radioactivity was measured by liquid scintillation in a Tri-Carb 2500 TR counter (Packard, Zurich, Switzerland).
  • the radioactivity was measured after addition of Microscint 40 scintillation fluid (Perkin Elmer, Boston MA) using a TopCount NXT (Packard)
  • the inhibition curves were fitted with a four parameter logistic equation giving IC50 values, and Hill coefficients.
  • Step 2 To a stirred solution of a compound of formulae III (1 eq) and urea (2 eq) in an organic solvent (e.g. MeOH) is added cone. HCl (e. g. MeOH/ HCl 10 : 1). The reaction mixture is heated under reflux conditions for about 40 h, water is added and the mixture is stirred at 0 0 C for 1 h. The precipitate is collected by filtration, washed with water and recrystallized (e.g. diethyl ether/hexan) to yield the compound of formulae IV.
  • organic solvent e.g. MeOH
  • Step 3 To a stirred solution of a compound of formulae IV in phosphoroxychloride is added DMF (5 - 10 drops) and the reaction mixture is stirred at 115°C for around 16 h, evaporated and ice- water is added. The water layer is extracted twice (e. g. with diethyl ether), the combined organic layer washed (water followed by brine), dried (e.g. MgSO/0 and evaporated to yield the compound of formulae V.
  • Step 4 To a stirred solution of a compound of formulae V ( 1 eq) in an organic solvent (e.g. 2-butanone) is added sodium iodide (3.5 eq) and hydroiodic acid (57% in water, 1 eq).
  • an organic solvent e.g. 2-butanone
  • reaction mixture is heated under reflux conditions for around 16 h, cooled and poured into ice/sat, sodium bicarbonate solution.
  • the water layer is extracted twice (e. g. with diethyl ether), the combined organic layer washed (water followed by brine), dried (e.g. MgSO/ t ) and evaporated. Further purification by column chromatography on silica gel (e.g toluene) yields the compound of formulae VI.
  • Step 1 To a vigourously stirred mixture of a carboxaldehyde compound of formula XVI (1.0 eq.), Rl-containing phosphonate compound of formula XVII (1.2 eq.) (optionally with additional THF (20 ml/50 mmol aldehyde) at 23 0 C (waterbath) was added a solution of potassium carbonate (2.0 eq.) in water (25 ml/50 mmol aldehyde) within 5 min and stirring was continued at 23 0 C for 1.5 h. Diluted with EtOAc, THF and water, separated phases, washed organic layer with brine, reextracted combined organic layer once with EtOAc, dried combined organic layer over Na2SO/t. Removal of the solvent in vacuum left the 3-aryl-prop-2-en-l -one-compound of formula XVIII, which was used without further purification.
  • Step 2 A stirred mixture of the 3-aryl-prop-2-en-l -one-compound of formula XVIII (1.0 eq.) and commercially available 1-ethoxycarbonylmethyl-pyridinium bromide [CAS-No. 17282-40-5] (1.1 eq.) and ammonium acetate (5 eq.) in a protic solvent (e.g. ethanol) was heated under reflux conditions for around 16 to 48 h.
  • a protic solvent e.g. ethanol
  • Step 3 To a stirred mixture of 4-aryl-2-pyridone of formula XIX (1.0 eq.) and phosphoryl bromide (1.0 to 3.0 eq.) in toluene is added DMF (0.3 to 0.4 eq.) and the reaction mixture is stirred at 105 to 115 0 C for around 2 to 24 h, evaporated and ice-water is added. The precipitated solid is filtered off, dissolved in an organic sovent (e.g. tert-butyl methyl ether or ethyl acetate), the organic layer is washed with sat.
  • an organic sovent e.g. tert-butyl methyl ether or ethyl acetate
  • Step 4 A stirred mixture of the 4-aryl-2-bromopyridines of formula XX (1.0 eq.), sodium iodide (2.0 eq.), copper(I) iodide (0.05 eq.) and N,N'-dimethylethylenediamine (DMEDA) (0.1 eq.) in 1,4-dioxane was heated at 110 0 C for ca. 1-2 h according to a procedure in /. Am. Chem. Soc. 2002, 124(50), 14844. Cooled to rt, diluted with TBME or ethyl acetate, washed with diluted ammonia solution and brine, dried over Na2SU4. Removal of the solvent in vacuum left a light yellow solid, which could be used directly or triturated with n-heptane to give the pure 4-aryl-2-iodopyridines of formula XXI.
  • Steps 1 and 2 are the same as in general procedure Ia.
  • Step 3 To a stirred mixture of 4-aryl-2-pyridone of formula XIX (1.0 eq.) in pyridine or ethyldiisopropyl amine/methylene chloride at temperatures between -15 and 0 0 C was added trifluoromethansulfonic anhydride (1.0 to 2.0 eq.) and stirring was continued at 0 0 C for 0.5 to 16 h. Poured into ice-water, extracted with ethyl acetate, washed with ice cold 1 M sulfuric acid, saturated NaHCO3-sol. and brine, dried over Na2SU4. Removal of the solvent in vacuum left the crude product as a brown solid which can be purified by silica gel column chromatography with heptane/EtOAc to give the pure triflates of general formula XXII.
  • a stirred mixture of a compound of formulae VI (1 eq), a imidazole derivative (1.5 eq) and potassium carbonate (1 eq) in an organic solvent (e.g. DMF) is heated at 130 0 C for around 45 min, cooled, poured into water and extracted three times with ethyl acetate. The combined organic layers are washed two times with brine, dried (e g. MgSCU) and evaporated.
  • the crude product is further purified by flash chromatography on silica gel (ethyl acetate/ heptane) and crystallization (e.g. ethyl acetate/ hexane) to give a compound of formulae X.
  • a boronic acid derivative (1.1 eq) an tetrakis(triphenylphosphine)palladium (0.03 eq) in an organic solvent (e.g. 1,2-dimethoxy-ethane) is added at room temperature IM sodium arbonate solution (2.5 eq), the reaction mixture is heated at 80 0 C for around 23 h, cooled, poured into ice-water and extracted two times with ethyl acetate. The combined organic layers are washed two times with brine, dried (e g. MgSCU) and evaporated.
  • an organic solvent e.g. 1,2-dimethoxy-ethane
  • Example B.3 2-(3-Bromo-phenyl)-4-(5-chloro-thiophen-2-yl)-6-trifluoromethyl-pyrimidine
  • the title compound was prepared from 2-chloro-4-(5-chloro-thiophen-2-yl)-6- trifluoromethyl-pyrimidine (example A.I) (1.2 g, 4.0 mmol) and commercially available 3-bromo-benzene-boronic acid (0.88 g, 4.38 mmol) according to the general procedure lib. Obtained as a white solid (0.73 g, 43%).
  • Example B.4 2-(3-Bromo-phenyl)-4-(5-chloro-thiophen-2-yl)-6-trifluoromethyl-pyrimidine
  • Example A.I 2-chloro-4-(5-chloro-thiophen-2-yl)-6
  • Step 1) 3-(6-Bromo-pyridin-2-yl)-N-tert-butyl-benzenesulfonamide: A mixture of commercially available 3-(tert-butylsulfamoyl)-benzeneboronic acid (5.142 g, 20 mmol), commercially available 2,6-dibromopyridine (14.2 g, 60 mmol) and Pd(PPh 3 ) 4 (1.156 g, 5 mol%) in DME (80 ml) and aqueous sodium carbonate (1 M, 40 ml, 40 mmol) was stirred at 90 0 C under argon atmosphere for 18 h.
  • Step 2 A mixture of the above described 3-(6-bromo-pyridin-2-yl)-N-tert-butyl- benzenesulfonamide (4.6 g, 12 mmol), hexabutyldistannane (9.9 ml, 19 mmol) and Pd(PPh 3 ) 4 (144 mg, 1 mol%) in toluene (135 ml) was stirred at 80 0 C for 18 h. The solvents were evaporated and the crude product directly purified by flash chromatography with n-heptane/ ethyl acetate to give the title compound (1.66 g, 23%) as a yellow oil. MS (ISP) 580.7 [(M+H) + ].
  • the general procedure IV allows the synthesis of pyrimidines of formula XV from 3-aryl- 2-alkyn-l-ones of formula XXVI and amidines of formula XXX as described in Synlett 2003, (2), 259-261.
  • a compound of formula XXIII, wherein the halide is preferably bromide or iodide, can be reacted with an 2-alkyn- 1 -ol of formula XXIV under so called Sonogashira conditions as for example described in Journal of Organic Chemistry 1998, 63(23), 8551-8553.
  • the nitrile of formula XXVIII can be prepared by someone skilled in the art from the corresponding bromides or iodides of formula XXVII by either palladium-catalyzed reaction with zinc or potassium cyanide or by reaction with copper(I) cyanide (CuCN).
  • the amidoximes of the formula XXIX can be prepared by someone skilled in the art by reaction a nitrile of formula XXVIII with hydroxylamine hydrochloride in aqueous methanol or ethanol in the presence of a base like e.g. sodium or potassium carbonate at temperatures between 23 and 80 0 C.
  • the amidines of formula XXX can be prepared by reduction of the amidoximes of formula XXIX by methods known to someone skilled in the art, like e.g. catalytic hydrogenation in the presence of a palladium-catalyst, like e.g. palladium on carbon, or rhodium-catalyst, like e.g. rhodium on alumina, or nickel- catalyst, like e.g. Raney-nickel, in protic solvents like e.g. ethanol, methanol or acetic acid (preferably in the presence of acetic anhydride as described in Synthetic Communications 1998, 28(23), 4419-4429).
  • a palladium-catalyst like e.g. palladium on carbon
  • rhodium-catalyst like e.g. rhodium on alumina
  • nickel- catalyst like e.g. Raney-nickel
  • protic solvents like e.g.
  • N-tert-Butyl-5- ⁇ 3-[4-trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2- yl] -phenyl ⁇ -thiophene-2-sulfonic acid amide was prepared from 2-(3-bromo-phenyl)-4- trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidine (example B.2) (0.448 g, 1.0 mmol) and N-tert-butyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-thiophene- 2-sulfonamide (example Cl) (0.414 g, 1.2 mmol) according to the general procedure III.
  • Example 18 5- ⁇ 3-[4-Difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yll-phenyl ⁇ - thiophene-2-sulfonic acid amide 1) N-tert-Butyl-5- ⁇ 3-[4-difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2- yl] -phenyl ⁇ -thiophene-2-sulfonic acid amide was prepared from 2-(3-bromo-phenyl)-4- difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidine (example B.6) (0.43 g, 1.0 mmol) and N-tert-butyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-thiophene-2- sulfonamide (example
  • N-tert-Butyl-5- ⁇ 3- [4-methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl] - phenyl ⁇ -thiophene-2-sulfonic acid amide was prepared from 2-(3-bromo-phenyl)-4- methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidine (example B.I 1) (0.197 g, 0.5 mmol) and N-tert-butyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-thiophene-2- sulfonamide (example Cl) (0.21 g, 0.6 mmol) according to the general procedure III.
  • N-tert-Butyl-3-(6-cyano-pyridin-2-yl)-benzenesulfonamide A mixture of the above described 3-(6-bromo-pyridin-2-yl)-N-tert-butyl-benzenesulfonamide (3.12 g, 8 mmol) and copper(I) cyanide (1.6 g, 18 mmol) in NMP (15 ml) was stirred at 120 0 C for 1 h. Cooled to rt, the reaction mixture was extracted with aqueous ammonia and ethyl acetate, the organic layers were dried over MgSO 4 , filtered and the solvents were evaporated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)

Abstract

The present invention relates to compounds of formula (I), a process for the manufacture thereof, their use for the preparation of medicaments for treating CNS disorders and pharmaceutical compositions containing them. Compounds of formula (I) are represented by general formula (I) wherein Q, A, B, X, Y, R 1 and R 2 are defined as in the specification.

Description

PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS
The present invention relates to compounds of formula (I), a process for the manufacture thereof, their use for the preparation of medicaments for treating CNS disorders and pharmaceutical compositions containing them.
In particular, the present invention relates to compounds of general formula (I)
either one of X or Y is N and the other is CH, or both X and Y are N;
Q is S, O, -CH=N- or -N=CH-;
A is aryl or 5 or 6 membered heteroaryl each of which is optionally substituted by C1-
6-alkyl; B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituents are selected from the group consisting of: halo, nitro,
Ci-6-alkyl optionally substituted by hydroxy, NRaRb, wherein Ra and Rb are independently H, C1-6-alkyl or -(CO)-C1-6- alkyl,
-S-Ci-6-alkyl, -(SO2)-OH, -(SO2)-C1-6-alkyl, -(SO2)-NRcRd, wherein Rc and Rd are independently:
H,
Ci-6-alkyl optionally substituted by hydroxy, Ci-6-haloalkyl,
HD/22.01.2008 Ci-6-alkoxy,
-(CO)Ci-6-alkyl optionally substituted by Ci-6-alkoxy, -(CH2CH2O)nCHR6, wherein Re is H or CH2OH and n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, -(CH2)m-aryl, wherein m is 1 or 2 and the aryl is optionally substituted by halo or Ci-6-alkoxy, -(CH2)p-C3-6-cycloalkyl, wherein p is 0 or 1, 5 or 6-membered heterocycloalkyl,
-(SO2)-NR Rg, wherein R and Rg together with the nitrogen atom to which they are attached form a 4, 5 or 6 membered heterocycloalkyl ring optionally containing a further heteroatom selected from nitrogen, oxygen, sulphur or a SO2 group, wherein said 4, 5 or 6 membered heterocycloalkyl ring is optionally substituted by a substituent selected from the group consisting of: hydroxy, Ci-6-alkyl, Ci-6-alkoxy which is optionally substituted by hydroxy, and 5 or 6 membered heteroaryloxy,
NHSO2-Ci-6-alkyl,
NHSO2-NR11R1 wherein Rh and R1 are independently H, C1-6-alkyl, -(CO)O- Ci-6-alkyl, or R and R1 together with the nitrogen atom to which they are attached form a 4, 5 or 6 membered heterocycloalkyl ring optionally containing a further heteroatom selected from nitrogen, oxygen or sulphur, wherein said 4, 5 or 6 membered heterocycloalkyl ring is optionally substituted by Ci-6-alkyl, R1 is H, halogen, Ci-6-alkyl optionally substituted by hydroxy, Ci-6-alkoxy, C1^- haloalkyl, C3-6-cycloalkyl; R2 is selected from the group consisting of: cyano, halogen, Ci-6-haloalkyl, Ci-6-alkoxy, Ci-6-haloalkoxy, Ci-6-alkyl and C3-6-cycloalkyl; or is NRJRk wherein R and Rk are independently selected from the group consisting of:
H, C3-8-cycloalkyl, aryl, heteroaryl having from 5 to 12 ring atoms and C1-O- alkyl which optionally substituted by one or more substituent(s) selected from the group consisting of halogen, hydroxy, C3-8-cycloalkyl, aryl, heteroaryl having from 5 to 12 ring atoms and -NR1R111, wherein R1 and R111 are independently selected from the group consisting of H and Ci-6-alkyl; or R and R111 can, together with the nitrogen atom to which they are attached, form an optionally substituted heterocyclic group comprising 5 to 12 ring atoms optionally containing a further heteroatom selected from nitrogen, oxygen or sulphur, wherein said heterocyclic group is optionally substituted by one, two, three, four or five substituents are selected from the group consisting of halogen, hydroxy, Ci-6-alkyl and Ci-6-haloalkyl; as well as pharmaceutically acceptable salts thereof.
It has surprisingly been found that the compounds of general formula I are metabotropic glutamate receptor antagonists. Compounds of formula I are distinguished by valuable therapeutic properties.
In the central nervous system (CNS) the transmission of stimuli takes place by the interaction of a neurotransmitter, which is sent out by a neuron, with a neuroreceptor.
L-glutamic acid, the most commonly occurring neurotransmitter in the CNS, plays a critical role in a large number of physiological processes. The glutamate-dependent stimulus receptors are divided into two main groups. The first main group forms ligand- controlled ion channels. The metabotropic glutamate receptors (mGluR) form the second main group and, furthermore, belong to the family of G-protein-coupled receptors.
At present, eight different members of these mGluR are known and of these some even have sub-types. On the basis of structural parameters, the different influences on the synthesis of secondary metabolites and the different affinity to low-molecular weight chemical compounds, these eight receptors can be sub-divided into three sub-groups: mGluRl and mGluR5 belong to group I, mGluR2 and mGluR3 belong to group II and mGluR4, mGluRό, mGluR7 and mGluR8 belong to group III.
Ligands of metabotropic glutamate receptors belonging to the group II can be used for the treatment or prevention of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits.
Other treatable indications in this connection are restricted brain function caused by bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest and hypoglycaemia. Further treatable indications are chronic and acute pain, Huntington's chorea, amyotrophic lateral sclerosis (ALS), dementia caused by AIDS, eye injuries, retinopathy, idiopathic parkinsonism or parkinsonism caused by medicaments as well as conditions which lead to glutamate-deficiency functions, such as e.g. muscle spasms, convulsions, migraine, urinary incontinence, nicotine addiction, opiate addiction, anxiety, vomiting, dyskinesia, depressions, colon cancer, sleep disorders, disorders of circadian rhythms and glioma since mGluR2 antagonists have been found to reduce cell proliferation in human glioma cells (J. Neurochem. March 2003, 84(6): 1288-95). - A -
Objects of the present invention are compounds of formula (I) and their pharmaceutically acceptable salts per se and as pharmaceutically active substances, their manufacture, medicaments based on a compound in accordance with the invention and their production, as well as the use of the compounds in accordance with the invention in the control or prevention of illnesses of the aforementioned kind, and, respectively, for the production of corresponding medicaments.
The compounds of formula (I) can also be used in form of their prodrugs. Examples are esters, N-oxides, phosphate esters, glycoamide esters, glyceride conjugates and the like. The prodrugs may add to the value of the present compounds advantages in absorption, pharmacokinetics in distribution and transport to the brain.
Unless otherwise stated, the following terms used in the present description have the definitions given in the following. The term "alkyl" denotes straight- chain or branched saturated hydrocarbon residues with 1 to 6 carbon atoms (Ci-6-alkyl), preferably with 1 to 4 carbon atoms, such as methyl, ethyl, n-propyl, i-propyl, i-butyl, t- butyl, as well as those groups which are illustrated with the exemplified compounds of the invention hereinafter.
The term "Ci-6-haloalkyl" denotes a Ci-6-alkyl group as defined hereinabove, which is substituted by one or more halogen atom(s), in particular Cl, F or I, preferably three Cl or two or three F, i.e. CCI3, CHF2 and CF3 as well as those groups which are specifically illustrated with the exemplified compounds of the invention hereinafter.
The term "Ci-6-alkoxy" denotes a Ci-6-alkyl residue in the sense of the foregoing definition bound via an oxygen atom. Examples of "Ci-6-alkoxy" residues include methoxy, ethoxy, isopropoxy, as well as those groups which are illustrated with the exemplified compounds of the invention hereinafter.
The term "Ci-6-haloalkoxy" denotes a Ci-6-alkoxy group as defined hereinabove, which is substituted by one or more halogen atom(s), in particular Cl, F or I, preferably three Cl or two or three F, i.e. OCHF2 and OCF3 , OCH2CHF2, OCH2CF3 as well as those groups which are specifically illustrated with the exemplified compounds of the invention hereinafter.
The term "aryl" denotes a monovalent cyclic aromatic hydrocarbon radical, for example phenyl, naphthyl, biphenyl or indanyl. The term "heteroaryl or 5 or 6-membered heteroaryl or heteroaryl having from 5 to 12 ring atoms" refers to an aromatic having 5 to 6 or 5 to 12 ring atoms and containing one or more, in particular, one, two, three, four or five and preferably one, two or three heteroatoms selected from nitrogen, oxygen or sulphur. Examples of such heteroaryl groups include thiophenyl, imidazolyl, oxadiazolyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl or pyridazinyl, and in particular, [1,2,4] oxadiazolyl, pyridin-2-yl, pyridin-3-yl, pyridine-4-yl, pyrimidin-5-yl, thiazol-2-yl and thiophen-2-yl as well as those groups which are illustrated with the exemplified compounds of the invention hereinafter.
The term "heteroaryloxy" denotes a heteroaryl group, including 5 or 6-membered heteroaryl or heteroaryl having from 5 to 12 ring atoms as defined hereinabove, which is connected via an oxygen atom.
The term "halogen" embraces fluorine (F), chlorine (Cl), bromine (Br) and iodine (I).
The term "C3-6-cycloalkyl or Cs-β-cycloalkyl" means a cycloalkyl group containing 3 to 6 or 5 to 8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl as those groups which are illustrated with the exemplified compounds of the invention hereinafter.
The term "5 or 6-membered or 5 to 12-membered heterocycloalkyl" denotes a heterocyclic ring having 5 or 6 or 5 to 12 ring members comprising at least two carbon atoms as ring member and 1, 2 or 3 additional heteroatom(s) ring members selected from N, O or S, the remaining ring members being carbon atoms. Examples of 5 or 12 heterocycloalkyl rings include but are not limited to lff-tetrazole; 2ff-tetrazole; 1,2,3- and 1,24-triazole; imidazole; pyrrole; 1,2,3-, 1,3,4- or 1,2,5- thiadiazine; 1,4-oxazine; 1,2- or 1,4-thiazine; 4-morpholinyl; 1 -pyrrolidinyl; 1 -piperazinyl, preferably 4-morpholinyl; 1 -pyrrolidinyl or 1 -piperazinyl as well as those groups which are illustrated with the exemplified compounds of the invention hereinafter. Substituents for such 5 or 6 membered heterocyclic ring include but are not limited to halo, amino, nitro, cyano, hydroxy, Ci-6-alkyl optionally substituted by hydroxy, Ci-6-alkoxy, Ci-6-alkenyl, C3-β- cycloalkyl, or CF3, and preferably Ci-6-alkyl or CF3 as well as those groups which are illustrated with the exemplified compounds of the invention hereinafter.
The term "optionally substituted" means that the chemical group to which it refers can be substituted by one or more of the substituents recited in this connection, for example by one, two, three, four, five, six, seven, eight, nine or ten substituents, depending on the valence and available positions of said chemical group.
The term "pharmaceutically acceptable addition salt" refers to any salt derived from an inorganic or organic acid or base.
The compounds of formula (I) and their pharmaceutically acceptable salts are metabotropic glutamate receptor antagonists and can be used for the treatment or prevention of acute and/or chronic neurological disorders, such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders and memory deficits. Other treatable indications are restricted brain function caused by bypass operations or transplants, poor blood supply to the brain, spinal cord injuries, head injuries, hypoxia caused by pregnancy, cardiac arrest and hypoglycaemia. Further treatable indications are acute and chronic pain, Huntington's chorea, ALS, dementia caused by AIDS, eye injuries, retinopathy, idiopathic parkinsonism or parkinsonism caused by medicaments as well as conditions which lead to glutamate-deficient functions, such as e.g. muscle spasms, convulsions, migraine, urinary incontinence, nicotine addiction, psychoses, opiate addiction, anxiety, vomiting, dyskinesia, depression, colon cancer, sleep disorders, disorders of circadian rhythms and glioma.
Also encompassed by the compounds of formula (I) according to the invention are the compounds wherein: both X and Y are N or X is N and Y is CH; Q is S, -CH=N-, or -N=CH-; A is aryl or 5 or 6 membered heteroaryl;
B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituents are selected from the group consisting of: NRaRb, wherein Ra and Rb are independently H,
-(SO2)-NRcRd, wherein Rc and Rd are independently: H,
Ci-6-alkyl, or -(CO)Ci-6-alkyl; R1 is Ci-6-alkyl or Ci-6-haloalkyl;
R2 is 5 or 6 membered heteroaryl optionally substituted by one, two or three substituents selected from the group consisting of: halogen and Ci-6-haloalkyl; as well as pharmaceutically acceptable salts thereof. Also encompassed by the compounds of formula (I) according to the invention are the compounds of formula (Ia):
wherein X, Y, Q, B, R1 and R2 are as described hereinabove for formula (I).
In a certain embodiment of the compounds of formula (Ia) B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituent is NRaRb, wherein Ra and Rb are both H, for example the following compounds:
5-{3-[4-(5-Chloro-thiophen-2-yl)-6-trifluoromethyl-pyrimidin-2-yl]-phenyl}- pyridin-2-ylamine;
5-{3-[4-(5-Chloro-thiophen-2-yl)-6-trifluoromethyl-pyrimidin-2-yl]-phenyl}- pyrimidin-2-ylamine; and
5-{3-[4-Trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]- phenyl } -pyridin - 2 -ylamine; 5- [3-(6'-Methyl-6-trifluoromethyl- [3,4']bipyridinyl-2'-yl)-phenyl] -pyridin-2- ylamine.
In a certain embodiment of the compounds of formula (Ia) B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituent is NRaRb, wherein Ra and Rb are H and -(SO2)-NRcRd, wherein Rc and Rd are independently H, Ci-6-alkyl, or -(CO)Ci-6-alkyl, for example the following compounds:
3'-[4-Trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]- biphenyl-3-sulfonic acid amide;
5-{3-[4-Trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]- phenyl} -thiophene-2-sulfonic acid amide;
3'-[4-(5-Chloro-thiophen-2-yl)-6-trifluoromethyl-pyrimidin-2-yl]-biphenyl-3- sulfonic acid amide;
5-{3-[4-(5-Chloro-thiophen-2-yl)-6-trifluoromethyl-pyrimidin-2-yl]-phenyl}- thiophene-2-sulfonic acid amide; 3'-[4-Difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]- biphenyl-3-sulfonic acid amide;
5-{3-[4-Difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]- phenyl}-thiophene-2-sulfonic acid amide; 3'- [4-Methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl] -biphenyl-3- sulfonic acid amide;
5-{3-[4-Methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]-phenyl}- thiophene-2-sulfonic acid amide;
3'-(6'-Methyl-6-trifluoromethyl-[3,4']bipyridinyl-2'-yl)-biphenyl-3-sulfonic acid tert-butylamide;
5- [3-(6'-Methyl-6-trifluoromethyl- [3,4']bipyridinyl-2'-yl)-phenyl] -pyridin-2- ylamine;
3'-(6'-Methyl-6-trifluoromethyl-[3,4']bipyridinyl-2'-yl)-biphenyl-3-sulfonic acid amide; and 5-[3-(6'-Methyl-6-trifluoromethyl-[3,4']bipyridinyl-2'-yl)-phenyl]-thiophene-2- sulfonic acid amide.
Also encompassed by the compounds of formula (I) according to the invention are the compounds of formula (Ib):
wherein X, Y, Q, B, R and R are as described hereinabove for formula (I).
In a certain embodiment of the compounds of formula (Ib) B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituent is NRaRb, wherein Ra and Rb are both H, for example the following compound: 4- [4-Trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl] - [2,3']bipyridinyl-6'-ylamine.
In a certain embodiment of the compounds of formula (Ib) B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituent is NRaRb, wherein Ra and Rb are H and -(SO2)-NRcRd, wherein Rc and Rd are independently H, Ci-6-alkyl, or -(CO)Ci-6-alkyl, for example the following compounds:
3-{4-[4-Trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]- pyridin - 2 -yl } -benzenesulfonamide; 5-{4- [4-Trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl] - pyridin-2-yl}-thiophene-2-sulfonic acid amide;
N-Propionyl-3-{4-[4-trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)- pyrimidin-2-yl] -pyridin-2-yl} -benzenesulfonamide;
3-{4-[4-Difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]- pyridin - 2 -yl } -benzenesulfonamide;
5-{4-[4-Difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]- pyridin-2-yl}-thiophene-2-sulfonic acid amide;
3-{4-[4-Methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]-pyridin-2-yl}- benzenesulfonamide; and 5-{4- [4-Methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl] -pyridin-2-yl} - thiophene-2-sulfonic acid amide.
Also encompassed by the compounds of formula (I) according to the invention are the compounds of formula (Ic):
wherein X, Y, Q, B, R1 and R2 are as described hereinabove for formula (I).
In a certain embodiment of the compounds of formula (Ic) B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituent is NRaRb, wherein Ra and Rb are H and -(SO2)-NRcRd, wherein Rc and Rd are independently H, Ci-6-alkyl, or -(CO)Ci-6-alkyl, for example the following compounds:
N-tert-Butyl-3-{6-[4-methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]- pyridin - 2 -yl } -benzenesulfonamide;
N-tert-Butyl-3-{6-[4-methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]- pyridin - 2 -yl } -benzenesulfonamide; 3-{6-[4-Methyl-6-(5-trifluoromethyl-pyridin-2-yl)-pyrimidin-2-yl]-pyridin-2-yl}- benzenesulfonamide;
3-{6-[4-Methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]-pyridin-2-yl}- benzenesulfonamide; N-tert-Butyl-3-(6'-methyl-6"-trifluoromethyl-[2,2';4',3"]terpyridin-6-yl)- benzenesulfonamide; and
3-(6'-Methyl-6"-trifluoromethyl-[2,2';4',3"]terpyridin-6-yl) -benzenesulfonamide.
Also encompassed by the compounds of formula (I) according to the invention are the compounds of formula (Id):
wherein X, Y, Q, B, R1 and R2 are as described hereinabove for formula (I).
In a certain embodiment of the compounds of formula (Id) B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituent is NRaRb, wherein Ra and Rb are both H, for example the following compounds:
5-{ l-[4-Trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]-lH- imidazol-4-yl}-pyridin-2-ylamine;
5-{ l-[4-Difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]-lH- imidazol-4-yl}-pyridin-2-ylamine; and
5-{ l-[4-Methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]-lH-imidazol- 4-yl}-pyridin-2-ylamine.
In a certain embodiment of the compounds of formula (Id) B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituent is NRaRb, wherein Ra and Rb are H and -(SO2)-NRcRd, wherein Rc and Rd are independently H, Ci-6-alkyl, or -(CO)Ci-6-alkyl, for example the following compounds:
3-{ l-[4-(5-Chloro-thiophen-2-yl)-6-trifluoromethyl-pyrimidin-2-yl]-lH- imidazol-4-yl} -benzenesulfonamide; and 5-{ l-[4-Methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]-lH-imidazol- 4-yl}-pyridin-2-ylamine.
The invention also encompasses processes for the preparation of the compounds of the invention.
The compounds of the invention can be prepared by a process comprising the steps of reacting a compound of formula (X):
with a boronic acid derivative of group B, wherein B is a defined hereinabove and a catalyst, to obtain the compound formula (XV):
wherein A, B, Q, R and R are as defined hereinabove.
The catalyst can be tetrakis(triphenylphosphine) -palladium.
The reaction can be performed in an organic solvent, e.g. dioxane.
The starting products, intermediates products and reagents for this process are either commercially available or can be prepared as described in the examples hereinafter. The compounds of the invention can also be prepared by a process comprising the steps of reacting a compound of formula (XXVI):
(XXVI) with a compound of formula (XXX):
wherein A, B, Q, R1 and R2 are as defined hereinabove.
The starting products, intermediates products and reagents for this process are either commercially available or can be prepared as described in the examples hereinafter.
All detailed procedures for the respective compounds can be found in the description of the examples.
The compounds of formula (I) and pharmaceutically acceptable salts thereof can be used as medicaments, e.g. in the form of pharmaceutical preparations. The pharmaceutical preparations can be administered orally, e.g. in the form of tablets, coated tablets, dragees, hard and soft gelatine capsules, solutions, emulsions or suspensions. However, the administration can also be effected rectally, e.g. in the form of suppositories, or parenterally, e.g. in the form of injection solutions.
The compounds of formula (I) and pharmaceutically acceptable salts thereof can be processed with pharmaceutically inert, inorganic or organic carriers for the production of pharmaceutical preparations. Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts and the like can be used, for example, as such carriers for tablets, coated tablets, dragees and hard gelatine capsules. Suitable carriers for soft gelatine capsules are, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols and the like; depending on the nature of the active substance no carriers are, however, usually required in the case of soft gelatine capsules. Suitable carriers for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar, glucose and the like. Adjuvants, such as alcohols, polyols, glycerol, vegetable oils and the like, can be used for aqueous injection solutions of water-soluble salts of compounds of formula (I), but as a rule are not necessary. Suitable carriers for suppositories are, for example, natural or hardened oils, waxes, fats, semi-liquid or liquid polyols and the like.
In addition, the pharmaceutical preparations can contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
As mentioned earlier, medicaments containing a compound of formula (I) or a pharmaceutically acceptable salt thereof and a therapeutically inert excipient are also an object of the present invention, as is a process for the production of such medicaments which comprises bringing one or more compounds of formula (I) or pharmaceutically acceptable salts thereof and, if desired, one or more other therapeutically valuable substances into a galenical dosage form together with one or more therapeutically inert carriers.
The dosage can vary within wide limits and will, of course, be fitted to the individual requirements in each particular case. In general, the effective dosage for oral or parenteral administration is between 0.01-20 mg/kg/day, with a dosage of 0.1-10 mg/ kg/ day being preferred for all of the indications described. The daily dosage for an adult human being weighing 70 kg accordingly lies between 0.7-1400 mg per day, preferably between 7 and 700 mg per day.
The present invention relates also to the use of compounds of formula (I) and of pharmaceutically acceptable salts thereof for the production of medicaments, especially for the control or prevention of acute and/or chronic neurological disorders of the aforementioned kind.
The compounds of the present invention are group II mGlu receptor antagonists.
The compounds show activities, as measured in the assay described below, of 0.250 μM or less, typically 0.100 μM or less, and ideally of 0.010 μM or less. In the table below are described some specific Ki values of some preferred compounds. Ex. No. 1 2 3 4 5 8 9
K1 mGlu2 (μM) 0. 0116 0. 0018 0 .012 0 .0143 0 .139 0. 0156 0. 0053
Ex. No. 10 12 13 17 19 20 25
Ki mGlu2 (μM) 0. 0066 0. 0033 0 .033 0 .0035 0 .015 0 .062 0 .105
Ex. No. 29 30 33
Ki mGlu2 (μM) 0 .026 0 .002 0 .042
[3Hl-LY354740 binding on mGlu2 transfected CHO cell membranes.
Transfection and cell culture
cDNA encoding the rat mGlu2 receptor protein in pBluescript II was subcloned into the eukaryotic expression vector pcDNA I-amp from Invitrogen Ltd (Paisley, UK). This vector construct (pcDlmGR2) was co-transfected with a psvNeo plasmid encoding the gene for neomycin resistance, into CHO cells by a modified calcium phosphate method described by Chen & Okayama (1988). The cells were maintained in Dulbecco's Modified Eagle medium with reduced L-glutamine ( 1 mM final concentration), 36mg/L L-Proline and 10 % dialysed foetal calf serum from Gibco-Invitrogen; the medium was supplemented with 500 microM α-methyl-4-carboxyphenylglycine (MCPG) . Selection was made in the presence of G-418 (300 ug/ml final concentration). Clones were identified by reverse transcription of 5 μg total RNA, followed by PCR using mGlu2 receptor specific primers 5'-atcactgcttgggtttctggcactg-3' and 5'- agcatcactgtgggtggcataggagc-3' in 60 mM Tris HCl (pH 10), 15 mM (NH4)2SO4, 2 mM MgCl2, 25 units/ml Taq Polymerase with 30 cycles annealing at 60 0C for 1 min., extention at 72 0C for 30 s, and 1 min. 95 0C denaturation.
Membrane preparation Cells, cultured as above, were harvested and washed three times with cold PBS and frozen at -80 0C. The pellet was resuspended in cold 20 mM HEPES-NaOH buffer containing 10 mM EDTA (pH 7.4), and homogenised with a polytron (Kinematica, AG, Littau, Switzerland) for 10 s at 10 000 rpm. After centrifugation for 30 min. at 4 0C, the pellet was washed once with cold 20 mM HEPES-NaOH buffer containing 0.1 mM EDTA, (pH 7.4). After a second centrifugation for 30 min. at 4 0C the pellet was resuspended in cold 20 mM HEPES-NaOH buffer containing 0.1 mM EDTA, (pH 7.4). Protein content was measured using the Micro BCA method from Pierce-Perbio (Rockford, IL, USA) using bovine serum albumin as standard.
[3H]-LY354740 binding
After thawing, the membranes were resuspended in cold 5OmM Tris-HCl buffer containing 2 mM MgCl2 (pH 7.4) (binding buffer). The final concentration of the membranes in the assays was 25 μg protein/ml. Inhibition experiments were performed with membranes incubated with 10 nM [3H]-LY354740 at room temperature, for 1 hour, in presence of various concentrations of the compound to be tested. Following the incubations, membranes were filtered onto Whatmann GF/B glass fiber filters or onto GF/B Unifilter plates and washed 5 times with cold binding buffer. Non specific binding was measured in the presence of 10 μM (2S,2'_R,3'i?)-2-(2'3'- Dicarboxycyclopropyl) glycine (DCG IV from Tocris, Ellisville, MO USA). After transfer of the filters into plastic vials containing 10 ml of Ultima- gold scintillation fluid from Perkin-Elmer (Boston, MA, USA), the radioactivity was measured by liquid scintillation in a Tri-Carb 2500 TR counter (Packard, Zurich, Switzerland). For 96-Unifilter plates the radioactivity was measured after addition of Microscint 40 scintillation fluid (Perkin Elmer, Boston MA) using a TopCount NXT (Packard)
Data analysis.
The inhibition curves were fitted with a four parameter logistic equation giving IC50 values, and Hill coefficients.
Synthesis of 2-chloro- and 2-iodo-pyrimidines In the following schemes and unless otherwise specified, A, B, Q, R1 and R2 are as defined hereinabove. General procedure I
Step 1:
To a stirred solution of compound of formula (I) in an organic solvent (e.g. tert-butyl- methyl-ether) is added at room temperature a solution of sodium methanolate in methanol followed by a solution of a compound of formula (II) in an organic solvent (e.g. tert-butyl-methyl-ether). The reaction mixture is stirred at room temperature for about 19 h, cooled, acidified and extracted (e.g. with diethyl ether). The combined organic layers are washed and dried (e.g. MgSCU) and evaporated to give crude the compound of formula (III) which can be used without further purification.
Step 2: To a stirred solution of a compound of formulae III (1 eq) and urea (2 eq) in an organic solvent (e.g. MeOH) is added cone. HCl (e. g. MeOH/ HCl 10 : 1). The reaction mixture is heated under reflux conditions for about 40 h, water is added and the mixture is stirred at 00C for 1 h. The precipitate is collected by filtration, washed with water and recrystallized (e.g. diethyl ether/hexan) to yield the compound of formulae IV. Step 3: To a stirred solution of a compound of formulae IV in phosphoroxychloride is added DMF (5 - 10 drops) and the reaction mixture is stirred at 115°C for around 16 h, evaporated and ice- water is added. The water layer is extracted twice (e. g. with diethyl ether), the combined organic layer washed (water followed by brine), dried (e.g. MgSO/0 and evaporated to yield the compound of formulae V. Step 4: To a stirred solution of a compound of formulae V ( 1 eq) in an organic solvent (e.g. 2-butanone) is added sodium iodide (3.5 eq) and hydroiodic acid (57% in water, 1 eq). The reaction mixture is heated under reflux conditions for around 16 h, cooled and poured into ice/sat, sodium bicarbonate solution. The water layer is extracted twice (e. g. with diethyl ether), the combined organic layer washed (water followed by brine), dried (e.g. MgSO/t) and evaporated. Further purification by column chromatography on silica gel (e.g toluene) yields the compound of formulae VI.
Synthesis of 2-bromo-, 2-iodo- and 2-trifluoromethanesulfonyloxy-4-aryl- pyridines
General procedures Ia and Ib
General procedure Ia (for bromides (XX) and iodides (XXI)):
Step 1: To a vigourously stirred mixture of a carboxaldehyde compound of formula XVI (1.0 eq.), Rl-containing phosphonate compound of formula XVII (1.2 eq.) (optionally with additional THF (20 ml/50 mmol aldehyde) at 23 0C (waterbath) was added a solution of potassium carbonate (2.0 eq.) in water (25 ml/50 mmol aldehyde) within 5 min and stirring was continued at 23 0C for 1.5 h. Diluted with EtOAc, THF and water, separated phases, washed organic layer with brine, reextracted combined organic layer once with EtOAc, dried combined organic layer over Na2SO/t. Removal of the solvent in vacuum left the 3-aryl-prop-2-en-l -one-compound of formula XVIII, which was used without further purification.
Step 2: A stirred mixture of the 3-aryl-prop-2-en-l -one-compound of formula XVIII (1.0 eq.) and commercially available 1-ethoxycarbonylmethyl-pyridinium bromide [CAS-No. 17282-40-5] (1.1 eq.) and ammonium acetate (5 eq.) in a protic solvent (e.g. ethanol) was heated under reflux conditions for around 16 to 48 h. After cooling to room temperature, the mixture was diluted with IM aqueous HCl (until pH 1 was achieved) and water, stirred for 30 min, the precipitate was filtered off, washed with water and was dried in air at 60 0C overnight to give the crude product, which was purified by trituration with diethyl ether/heptane to give the pure 4-aryl-2-pyridone of general formula XIX.
Step 3: To a stirred mixture of 4-aryl-2-pyridone of formula XIX (1.0 eq.) and phosphoryl bromide (1.0 to 3.0 eq.) in toluene is added DMF (0.3 to 0.4 eq.) and the reaction mixture is stirred at 105 to 115 0C for around 2 to 24 h, evaporated and ice-water is added. The precipitated solid is filtered off, dissolved in an organic sovent (e.g. tert-butyl methyl ether or ethyl acetate), the organic layer is washed with sat. NaHCθ3-sol., then with brine and finally dried over MgSCv Filtration and removal of the solvent in vacuum gave the crude material, which is either used without further purification or is purified by silica gel column chromatography (optionally followed by trituration with n-heptane) to give the pure 4-aryl-2-bromopyridines of formula XX.
Step 4: A stirred mixture of the 4-aryl-2-bromopyridines of formula XX (1.0 eq.), sodium iodide (2.0 eq.), copper(I) iodide (0.05 eq.) and N,N'-dimethylethylenediamine (DMEDA) (0.1 eq.) in 1,4-dioxane was heated at 110 0C for ca. 1-2 h according to a procedure in /. Am. Chem. Soc. 2002, 124(50), 14844. Cooled to rt, diluted with TBME or ethyl acetate, washed with diluted ammonia solution and brine, dried over Na2SU4. Removal of the solvent in vacuum left a light yellow solid, which could be used directly or triturated with n-heptane to give the pure 4-aryl-2-iodopyridines of formula XXI.
General procedure Ib (for triflates (XXII)):
Steps 1 and 2 are the same as in general procedure Ia.
Step 3: To a stirred mixture of 4-aryl-2-pyridone of formula XIX (1.0 eq.) in pyridine or ethyldiisopropyl amine/methylene chloride at temperatures between -15 and 0 0C was added trifluoromethansulfonic anhydride (1.0 to 2.0 eq.) and stirring was continued at 0 0C for 0.5 to 16 h. Poured into ice-water, extracted with ethyl acetate, washed with ice cold 1 M sulfuric acid, saturated NaHCO3-sol. and brine, dried over Na2SU4. Removal of the solvent in vacuum left the crude product as a brown solid which can be purified by silica gel column chromatography with heptane/EtOAc to give the pure triflates of general formula XXII. Example A.I
2-Chloro-4-(5-chloro-thiophen-2-yl)-6-trifluoromethyl-pyrimidine
1) 4-(5-Chloro-thiophen-2-yl)-6-trifluoromethyl-lH-pyrimidin-2-one: The compound was prepared from commercially available ethyl acetate, commercially available 5-acetyl- 2-chloro-thiophene (10.0 g, 0.06 mol) and urea according to the general procedure I. Obtained as a light yellow solid (10.6 g, 61%). MS (ISP) 281.0 [(M+H)+]; mp 191°C. 2) The title compound was prepared from 4-(5-chloro-thiophen-2-yl)-6-trifluoromethyl- lH-pyrimidin-2-one (10.0 g, 35.6 mmol) and phosphoroxychloride (50 ml) according to the general procedure I. Obtained as a brown oil (10.4 g, 98%). MS (EI) 298.0, 299.9 [(M)+].
Example A.2
2-Chloro-4-trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidine
1) 4-(6-Trifluoromethyl-pyridin-3-yl)-6-trifluoromethyl-lH-pyrimidin-2-one: The compound was prepared from commercially available ethyl trifluoroacetate, commercially available l-[6-(trifluoromethyl)pyridin-3-yl]ethanone [CAS-No. 358780- 14-0] and urea according to the general procedure I. Obtained as a light brown solid (6.98 g, 85%). MS (ISP) 310.2 [(M+H)+]; mp 221°C. 2) The title compound was prepared from 4-(6-trifluoromethyl-pyridin-3-yl)-6- trifluoromethyl-lH-pyrimidin-2-one (6.87 g, 0.022 mol) and phosphoroxychloride (35 ml) according to the general procedure I. Obtained as a light brown solid (7.18 g, 99%). MS (ISP) 329.2 [(MH-H)+] ; mp 87°C.
Example A.3
2-Chloro-4-difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidine
1) 6-Difluoromethyl-4-(6-trifluoromethyl-pyridin-3-yl)-lH-pyrimidin-2-one: The compound was prepared from commercially available ethyl difluoroacetate, commercially available l-[6-(trifluoromethyl)pyridin-3-yl]ethanone [CAS-No. 358780-14-0] and urea according to the general procedure I. Obtained as a light brown solid (6.37 g, 84%). MS (ISP) 292.1 [(M+H)+]; mp 205.50C.
2) The title compound was prepared from 6-difluoromethyl-4-(6-trifluoromethyl- pyridin-3-yl)- lH-pyrimidin-2-one (6.37 g, 0.022 mol) and phosphoroxychloride (34 ml) according to the general procedure I. Obtained as a brown oil (6.65 g, 98%). MS (ISP) 310.2 [(M+H)+].
Example A.4
2-Chloro-4-methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidine
1) 6-Methyl-4-(6-trifluoromethyl-pyridin-3-yl)-lH-pyrimidin-2-one: The compound was prepared from commercially available ethyl acetate, commercially available l-[6- (trifluoromethyl)pyridin-3-yl]ethanone [CAS-No. 358780-14-0] and urea according to the general procedure I. Obtained as a light yellow solid (2.0 g, 31%). MS (ISP) 256.2 [(M+H)+]; mp 250.5°C.
2) The title compound was prepared from 6-methyl-4-(6-trifluoromethyl-pyridin-3-yl)- lH-pyrimidin-2-one (2.0 g, 7.84 mmol) and phosphoroxychloride (12 ml) according to the general procedure I. Obtained as an orange solid (1.33 g, 62%). MS (ISP) 274.1 [(MH-H)+]; mp 123.5 0C.
Example A.5
Trifluoro-methanesulfonic acid 6'-methyl-6-trifluoromethyl-[3,4']bipyridinyl-2'-yl ester
1 ) (E)-4-(6-Trifluoromethyl-pyridin-3-yl)-but-3-en-2-one: Prepared from commercially available 6-(trifluoromethyl)pyridine-3-carboxaldehyde [CAS-no. 386704-12-7] (5 g, 29 mmol), commercially available dimethyl-2-oxopropylphosphonate (4.8 mL, 35 mmol) and K2CO3 (7.97 g, 58 mmol) in water (60 mL) according to the general procedure Ia step 1. MS (ISP) 216.1 [(MH-H)+].
2) 6'-Methyl-6-trifluoromethyl-lΗ-[3,4']bipyridinyl-2'-one: Prepared from the above described (£)-4-(6-trifluoromethyl-pyridin-3-yl)-but-3-en-2-one (6.6 g, 28 mmol, 91% purity), commercially available 1-ethoxycarbonylmethyl-pyridinium bromide [CAS-No. 17282-40-5] (7.58 g, 31 mmol) and ammonium acetate (10.8 g, 140 mmol) in EtOH (45 mL) according to general procedure Ia step 2. Obtained as a light yellow solid (2.0 g, 29%). MS (ISP) 255.1 [(MH-H)+]. 3) The title compound was prepared from the above described 6'-methyl-6- trifluoromethyl-r#H!-[3,4']bipyridinyl-2'-one (2.0 g, 8 mmol), diisopropylethylamine (5.4 ml, 32 mmol) and trifluoromethanesulfonic anhydride (3.2 mL, 19 mmol) according to the general procedure Ib step 3. Obtained as a light brown solid (1.75 g, 58%). MS (ISP) 387.1 [(M+H)+].
Synthesis of bromo- and chloro derivatives (coupling partners)
General procedure Ha (C,N connection)
A stirred mixture of a compound of formulae VI (1 eq), a imidazole derivative (1.5 eq) and potassium carbonate (1 eq) in an organic solvent (e.g. DMF) is heated at 1300C for around 45 min, cooled, poured into water and extracted three times with ethyl acetate. The combined organic layers are washed two times with brine, dried (e g. MgSCU) and evaporated. The crude product is further purified by flash chromatography on silica gel (ethyl acetate/ heptane) and crystallization (e.g. ethyl acetate/ hexane) to give a compound of formulae X.
General procedure lib (C,C connection A)
To a stirred mixture of a compound of formulae VI or VII ( 1 eq), a boronic acid derivative (1.1 eq) an tetrakis(triphenylphosphine)palladium (0.03 eq) in an organic solvent (e.g. 1,2-dimethoxy-ethane) is added at room temperature IM sodium arbonate solution (2.5 eq), the reaction mixture is heated at 80 0C for around 23 h, cooled, poured into ice-water and extracted two times with ethyl acetate. The combined organic layers are washed two times with brine, dried (e g. MgSCU) and evaporated. The crude product is further purified by flash chromatography on silica gel (ethyl acetate/ heptane) and crystallization (e.g. dichloromethane/ hexane) to give a compound of formulae X. General procedure Hc (C,C connection B)
To a stirred solution of commercially available 2-chloro-4-iodo-pyridine [CAS No. 153034-86-7] ( 1 eq) in an organic solvent (e.g. THF) is added at -65 0C iso- propylmagnesium chloride (2M in THF, 1 eq), the mixture is stirred at -45°C for around 45 min. and zinc chloride (IM in THF, 1.1 eq) is added. The reaction mixture is stirred at room temperature for around 45 min, a compound of formulae VI or VII is added, the reaction mixture is stirred at 50 0C for around 16 h, cooled, poured into ice-saturated NaHCθ3 solution and extracted two times with ethyl acetate. The combined organic layers are washed with brine, dried (e g. MgSCU) and evaporated. The crude product is further purified by column chromatography on silica gel (toluene) to give a compound of formulae X.
Example B.I
4-(5-Chloro-thiophen-2-yl)-2-(4-iodo-imidazol-l-yl)-6-trifluoromethyl-pyrimidine The title compound was prepared from 2-chloro-4-(5-chloro-thiophen-2-yl)-6- trifluoromethyl-pyrimidine (example A.I) (1.2 g, 4.0 mmol) and commercially available 4-iodo-imidazole (0.85 g, 4.4 mmol) according to the general procedure Ha. Obtained as an off-white solid (1.78 g, 97%). MS (ISP) 457.0 [(M+H)+]; mp 251 0C.
Example B.2
2-(3-Bromo-phenyl)-4-trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidine The title compound was prepared from 2-chloro-4-trifluoromethyl-6-(6-trifluoromethyl- pyridin-3-yl)-pyrimidine (example A.2) (1.50 g, 4.38 mmol) and commercially available 3-bromo-benzene-boronic acid (1.01 g, 5.03 mmol) according to the general procedure lib. Obtained as a white solid (1.15 g, 56%). MS (EI) 448.0, 450.0 [(M)+]; mp 1600C.
Example B.3 2-(3-Bromo-phenyl)-4-(5-chloro-thiophen-2-yl)-6-trifluoromethyl-pyrimidine The title compound was prepared from 2-chloro-4-(5-chloro-thiophen-2-yl)-6- trifluoromethyl-pyrimidine (example A.I) (1.2 g, 4.0 mmol) and commercially available 3-bromo-benzene-boronic acid (0.88 g, 4.38 mmol) according to the general procedure lib. Obtained as a white solid (0.73 g, 43%). MS (EI) 419.9 [(M)+]; mp 124°C. Example B.4
2-(2-Chloro-pyridin-4-yl)-4-trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)- pyrimidine The title compound was prepared from 2-chloro-4-trifluoromethyl-6-(6-trifluoromethyl- pyridin-3-yl) -pyrimidine (example A.2) (2.0 g, 6.1 mmol) and commercially available 2- chloro-pyridine-4-boronic acid (1.06 g, 6.74 mmol) according to the general procedure lib. Obtained as a light brown solid (0.94 g, 38%). MS (ISN) 405.2 [(M-H)"]; mp 148.5°C.
Example B.5
2-(4-Iodo-imidazol-l-yl)-4-trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)- pyrimidine The title compound was prepared from 2-chloro-4-trifluoromethyl-6-(6-trifluoromethyl- pyridin-3-yl) -pyrimidine (example A.2) ( 1.31 g, 4.0 mmol) and commercially available 4- iodo-imidazole (0.85 g, 4.4 mmol) according to the general procedure Ha. Obtained as a light brown solid ( 1.84 g, 95%). MS (ISP) 486.9 [(M+H)+]; mp 179°C.
Example B.6
2-(3-Bromo-phenyl)-4-difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl) -pyrimidine The title compound was prepared from 2-chloro-4-difluoromethyl-6-(6-trifluoromethyl- pyridin-3-yl) -pyrimidine (example A.3) (2.0 g, 6.46 mmol) and commercially available 3- bromo-benzene-boronic acid ( 1.43 g, 7.12 mmol) according to the general procedure lib. Obtained as a white solid (0.89 g, 32%). MS (ISP) 430.1 [(M+H)+]; mp 148.5°C.
Example B.7
2-(2-Chloro-pyridin-4-yl)-4-difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)- pyrimidine The title compound was prepared from 2-chloro-4-difluoromethyl-6-(6-trifluoromethyl- pyridin-3-yl) -pyrimidine (example A.3) (2.0 g, 6.46 mmol) and commercially available 2- chloro-pyridine-4-boronic acid ( 1.12 g, 7.12 mmol) according to the general procedure lib. Obtained as an off-white solid (0.6 g, 24%). MS (ISP) 387.1 [(M+H)+]; mp 185°C. Example B.8
4-Difluoromethyl-2-(4-iodo-imidazol-l-yl)-6-(6-trifluoromethyl-pyridin-3-yl)- pyrimidine The title compound was prepared from 2-chloro-4-difluoromethyl-6-(6-trifluoromethyl- pyridin-3-yl) -pyrimidine (example A.3) (1.24 g, 4.0 mmol) and commercially available 4- iodo-imidazole (0.85 g, 4.4 mmol) according to the general procedure Ha. Obtained as a light brown solid (1.77 g, 95%). MS (ISP) 468.0 [(M+H)+]; mp 173°C.
Example B.9
2-(4-Iodo-imidazol-l-yl)-4-methyl-6-(6-trifluoromethyl-pyridin-3-yl) -pyrimidine The title compound was prepared from 2-chloro-4-methyl-6-(6-trifluoromethyl-pyridin- 3 -yl) -pyrimidine (example A.4) (0.27 g, 1.0 mmol) and commercially available 4-iodo- imidazole (0.21 g, 1.1 mmol) according to the general procedure Ha. Obtained as a light brown solid (0.35 g, 81%). MS (ISP) 432.1 [(M+H)+]; mp 193.5°C.
Example B.10
2-(2-Chloro-pyridin-4-yl)-4-methyl-6-(6-trifluoromethyl-pyridin-3-yl) -pyrimidine The title compound was prepared from 2-chloro-4-methyl-6-(6-trifluoromethyl-pyridin- 3 -yl) -pyrimidine (example A.4) (0.63 g, 2.3 mmol) and commercially available 2-chloro- pyridine-4-boronic acid (0.4 g, 2.53 mmol) according to the general procedure lib. Obtained as a light yellow solid (0.53 g, 65%). MS (ISP) 351.1 [(M+H)+]; mp 183.5°C.
Example B.ll 2-(3-Bromo-phenyl)-4-methyl-6-(6-trifluoromethyl-pyridin-3-yl) -pyrimidine
The title compound was prepared from 2-chloro-4-methyl-6-(6-trifluoromethyl-pyridin- 3 -yl) -pyrimidine (example A.4) (0.41 g, 1.5 mmol) and commercially available 3-bromo- benzene-boronic acid (0.33 g, 1.64 mmol) according to the general procedure lib. Obtained as a light yellow solid (0.30 g, 51%). MS (ISP) 394.0 [(M+H)+]; mp 1300C.
Example B.12
6'-(3-Bromo-phenyl)-2'-methyl-6-trifluoromethyl-[3,4'lbipyridinyl The title compound was prepared from trifluoro-methanesulfonic acid 6'-methyl-6- trifluoromethyl-[3,4']bipyridinyl-2'-yl ester (example A.5) (0.773 g, 2.0 mmol) and commercially available 3-bromo-benzene-boronic acid (0.43 g, 2.1 mmol) according to the general procedure lib. Obtained as a white solid (0.69 g, 88%). MS (ISP) 393.1 [(M+H)+] and 395.1 [(M+2+H)+].
Example Cl N-tert-Butyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-thiophene-2-sulfonamide
To a stirred solution of commercially available 5-bromo-N-tert-butyl-thiophene-2- sulfonamide (16.9 g, 56.7 mmol) and commercially available triisopropyl borate (39.4 g, 0.21 mol) in THF (500 ml) was added dropwise at -78°C n-butyllithium (1.6 M in hexane, 131 ml, 0.21 mol) in a way that the temperature did not exceed -65°C. The mixture was allowed to stirr for 3 h at -78°C and afterwards water (500 ml) was added dropwise at -20 0C. The layers were separated, the water phase was extracted with diethylether (4 x 200 ml) and afterwards 2N HCl was added (120 ml). The acidic water layer was extracted with ethyl actetate (3 x 200 ml), the combined organic layers were dried (MgSO4) and evaporated to yield a light brown gum (12.3 g, 83%), which was dissolved in toluene (400 ml). Pinakol (16.6 g, 0.14 mol) and p-toluenesulfonic acid (0.27 g, 1.41 mmol) was added, the reaction mixture was heated under reflux conditions for 3 h and evaporated to yield a light brown oil. Hexane (50 ml) was added and the mixture was stirred at room temperature for 30 min. The precipitate was collected by filtration, washed with hexane and dried to yield the title compound as an off-white solid (9.3 g, 57%). MS (EI) 345.2 [(M)+]; mp 127°C.
Example C.2
N-tert-Butyl-3-(6-tributylstannanyl-pyridin-2-yl)-benzenesulfonamide
Step 1) 3-(6-Bromo-pyridin-2-yl)-N-tert-butyl-benzenesulfonamide: A mixture of commercially available 3-(tert-butylsulfamoyl)-benzeneboronic acid (5.142 g, 20 mmol), commercially available 2,6-dibromopyridine (14.2 g, 60 mmol) and Pd(PPh3)4 (1.156 g, 5 mol%) in DME (80 ml) and aqueous sodium carbonate (1 M, 40 ml, 40 mmol) was stirred at 90 0C under argon atmosphere for 18 h. The reaction mixture was extracted with water and ethyl acetate, the organic layers dried over MgSO4, filtered and the solvents evaporated. The crude product was purified by flash chromatography with n- heptane/ ethyl acetate to give the 3-(6-bromo-pyridin-2-yl)-N-tert-butyl- benzenesulfonamide (6.60 g, 89%) as a yellow solid. MS (ISP) 369.1 [(M+H)+] and 371.0 [(M+2+H)"1"].
Step 2) A mixture of the above described 3-(6-bromo-pyridin-2-yl)-N-tert-butyl- benzenesulfonamide (4.6 g, 12 mmol), hexabutyldistannane (9.9 ml, 19 mmol) and Pd(PPh3)4 (144 mg, 1 mol%) in toluene (135 ml) was stirred at 80 0C for 18 h. The solvents were evaporated and the crude product directly purified by flash chromatography with n-heptane/ ethyl acetate to give the title compound (1.66 g, 23%) as a yellow oil. MS (ISP) 580.7 [(M+H)+].
General procedure HI
To a stirred mixture of a compound of formulae X ( 1 eq), a boronic acid derivative ( 1 eq) and tetrakis(triphenylphosphine)palladium (0.1 eq) in an organic solvent (e.g. dioxane) is added at room temperature IM sodium carbonate solution (2 eq), the reaction mixture is heated under reflux conditions for around 18 h, cooled, poured into ice- water and extracted two times with ethyl acetate. The combined organic layers are washed two times with brine, dried (e g. MgSO4) and evaporated. The crude product is further purified by column chromatography on silica gel (e.g. MeCl2(MeOH/NH4OH 20:1:0.1) and crystallization (e.g. dichloro methane/ MeOH/ hexane) to give a compound of formulae XV.
General procedure IV
The general procedure IV allows the synthesis of pyrimidines of formula XV from 3-aryl- 2-alkyn-l-ones of formula XXVI and amidines of formula XXX as described in Synlett 2003, (2), 259-261. A compound of formula XXIII, wherein the halide is preferably bromide or iodide, can be reacted with an 2-alkyn- 1 -ol of formula XXIV under so called Sonogashira conditions as for example described in Journal of Organic Chemistry 1998, 63(23), 8551-8553. The resulting 3-aryl-2-alkyn-l-ol of formula XXV can be oxidized to the corresponding 3- aryl-2-alkyn-l-one of formula XXVI by many methods known to someone skilled in the art, e.g. by so called Jones oxidation with chromium(VI) oxide (CrOs) in a mixture of aqueous sulfuric acid and acetone, Dess-Martin Periodinane (DMP) in methylene chloride, so called Swern oxidation (oxalyl chloride, dimethyl sulfoxide, triethylamine in methylene chloride, pyridinium chlorochromate (PCC) or pyridinium dichromate (PDC)in methylene chloride, manganese(IV) oxide (MnC^) in methylene chloride or acetone. The nitrile of formula XXVIII can be prepared by someone skilled in the art from the corresponding bromides or iodides of formula XXVII by either palladium-catalyzed reaction with zinc or potassium cyanide or by reaction with copper(I) cyanide (CuCN). The amidoximes of the formula XXIX can be prepared by someone skilled in the art by reaction a nitrile of formula XXVIII with hydroxylamine hydrochloride in aqueous methanol or ethanol in the presence of a base like e.g. sodium or potassium carbonate at temperatures between 23 and 80 0C. The amidines of formula XXX can be prepared by reduction of the amidoximes of formula XXIX by methods known to someone skilled in the art, like e.g. catalytic hydrogenation in the presence of a palladium-catalyst, like e.g. palladium on carbon, or rhodium-catalyst, like e.g. rhodium on alumina, or nickel- catalyst, like e.g. Raney-nickel, in protic solvents like e.g. ethanol, methanol or acetic acid (preferably in the presence of acetic anhydride as described in Synthetic Communications 1998, 28(23), 4419-4429).
All detailed procedures for the respective compounds can be found in the description of the examples.
Example 1
3-{ l- [4-(5-Chloro-thiophen-2-yl)-6-trifluoromethyl-pyrimidin-2-yll -lH-imidazol-4-yl}- benzenesulfonamide
1) N-tert-Butyl-3-{ l- [4-(5-chloro-thiophen-2-yl)-6-trifluoromethyl-pyrimidin-2-yl] - lH-imidazol-4-yl} -benzenesulfonamide was prepared from 4-(5-chloro-thiophen-2-yl)- 2-(4-iodo-imidazol-l-yl)-6-trifluoromethyl-pyrimidine (example B.I) (0.46 g, 1.0 mmol) and commercially available 3-(tert.-butylsulfamoyl)-phenylboronic acid (0.28 g, 1.1 mmol) according to the general procedure III. Obtained as a light yellow solid (0.3 g) which was subsequently deprotected. 2) To a cooled and stirred solution of N-tert-butyl-3-{ l- [4-(5-chloro-thiophen-2-yl)-6- trifluoromethyl-pyrimidin-2-yl] -lH-imidazol-4-yl} -benzenesulfonamide (0.3 g) in dichloromethane (6 ml) was added TFA (6 ml) and the reaction mixture was allowed to stir at room temperature for 15 h. The mixture was evaporated to dryness, poured into 2N NaHCθ3 solution (20 ml) and extracted with ethyl acetate (2 x 30 ml). The combined organic layers were washed with brine (20 ml), dried (MgSO/O and evaporated. Further purification by flash chromatography on silica gel (ethyl acetate/ heptane) and crystallization (dichloromethane/ MeOH/ hexane) yielded the title compound as an off- white solid (0.08 g, 16%). MS (ISP) 485.9 [ (MH-H)+] ; mp 189 0C.
Example 2
3'- [4-Trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yll -biphenyl-3- sulfonic acid amide
1) 3'-[4-Trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl] -biphenyl-3- sulfonic acid tert-butylamide was prepared from 2-(3-bromo-phenyl)-4-trifluoromethyl- 6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidine (example B.2) (0.448 g, 1.0 mmol) and commercially available 3-(tert.-butylsulfamoyl)-phenylboronic acid (0.31 g, 1.2 mmol) according to the general procedure III. Obtained as light yellow solid (0.56 g), which was subsequently deprotected.
2) To a cooled and stirred solution of 3'- [4-trifluoromethyl-6-(6-trifluoromethyl- pyridin-3-yl)-pyrimidin-2-yl] -biphenyl-3-sulfonic acid tert-butylamide (0.56 g) in dichloromethane (6 ml) was added TFA (6 ml) and the reaction mixture was allowed to stir at room temperature for 15 h. The mixture was evaporated to dryness, poured into 2N Na2CO3 solution (25 ml) and extracted with ethyl acetate (3 x 50 ml). The combined organic layers were washed with brine (50 ml), dried (MgSO/0 and evaporated. Further purification by crystallization (ethyl acetate/ heptane) yielded the title compound as a white solid (0.39 g, 74%). MS (ISP) 525.2 [(MH-H)+]; mp 211 0C. Example 3
5-{3-[4-Trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yll -phenyl}- thiophene-2-sulfonic acid amide
1) N-tert-Butyl-5-{3-[4-trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2- yl] -phenyl} -thiophene-2-sulfonic acid amide was prepared from 2-(3-bromo-phenyl)-4- trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidine (example B.2) (0.448 g, 1.0 mmol) and N-tert-butyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-thiophene- 2-sulfonamide (example Cl) (0.414 g, 1.2 mmol) according to the general procedure III. Obtained as an off-white solid (0.45 g), which was subsequently deprotected. 2) To a cooled and stirred solution of N-tert-butyl-5-{3-[4-trifluoromethyl-6-(6- trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl] -phenyl} -thiophene-2-sulfonic acid amide (0.45 g) in dichloromethane (6 ml) was added TFA (6 ml) and the reaction mixture was allowed to stir at room temperature for 15 h. The mixture was evaporated to dryness, poured into 2N Na2CO3 solution (25 ml) and extracted with ethyl acetate (3 x 50 ml). The combined organic layers were washed with brine (50 ml), dried (MgSO/O and evaporated. Further purification by flash chromatography on silica gel (ethyl acetate/ heptane) and crystallization (ethyl acetate/ heptane) yielded the title compound as a light yellow solid (0.2 g, 38%). MS (ISP) 531.0 [(MH-H)+] ; mp 250.5 0C.
Example 4
3'-[4-(5-Chloro-thiophen-2-yl)-6-trifluoromethyl-pyrimidin-2-yll-biphenyl-3-sulfonic acid amide 1) 3'-[4-(5-Chloro-thiophen-2-yl)-6-trifluoromethyl-pyrimidin-2-yl]-biphenyl-3- sulfonic acid tert-butylamide was prepared from 2-(3-bromo-phenyl)-4-(5-chloro- thiophen-2-yl)-6-trifluoromethyl-pyrimidine (example B.3) (0.42 g, 1.0 mmol) and commercially available 3-(tert.-butylsulfamoyl)-phenylboronic acid (0.334 g, 1.3 mmol) according to the general procedure III. Obtained as an off-white solid (0.22 g), which was subsequently deprotected. 2) To a cooled and stirred solution of 3'-[4-(5-chloro-thiophen-2-yl)-6-trifluoromethyl- pyrimidin-2-yl]-biphenyl-3-sulfonic acid tert-butylamide (0.22 g) in dichloromethane (5 ml) was added TFA (5 ml) and the reaction mixture was allowed to stir at room temperature for 15 h. The mixture was evaporated, poured into saturated NaHCθ3 solution (20 ml) and extracted with ethyl acetate (2 x 30 ml). The combined organic layers were washed with brine (20 ml), dried (MgSO/0 and evaporated. Further purification by flash chromatography on silica gel (ethyl acetate/ heptane) and crystallization (MeOH) yielded the title compound as a light yellow solid (0.13 g, 27%). MS (ISN) 494.3 [(M-H)"]; mp 226.5 0C.
Example 5 5-{3-[4-(5-Chloro-thiophen-2-yl)-6-trifluoromethyl-pyrimidin-2-yll-phenyl}-pyridin-2- ylamine
The title compound was prepared from 2-(3-bromo-phenyl)-4-(5-chloro-thiophen-2- yl)-6-trifluoromethyl-pyrimidine (example B.3) (0.25 g, 0.6 mmol) and commercially available 2-amino-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (0.157 g, 0.71 mmol) according to the general procedure III. Obtained as a yellow solid (0.083 g, 32%). MS (ISP) 433.2 [(M+H)+]; mp 99 0C.
Example 6
5-{3-[4-(5-Chloro-thiophen-2-yl)-6-trifluoromethyl-pyrimidin-2-yll-phenyl}- pyrimidin-2-ylamine The title compound was prepared from 2-(3-bromo-phenyl)-4-(5-chloro-thiophen-2- yl)-6-trifluoromethyl-pyrimidine (example B.3) (0.31 g, 0.74 mmol) and commercially available 2-amino-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyrimidine (0.18 g, 0.81 mmol) according to the general procedure III. Obtained as a light yellow solid (0.075 g, 23%). MS (ISP) 434.2 [(M+H)+]; mp 228 0C.
Example 7
5-{3-[4-(5-Chloro-thiophen-2-yl)-6-trifluoromethyl-pyrimidin-2-yll-phenyl}- thiophene-2-sulfonic acid amide 1) 5-{3-[4-(5-Chloro-thiophen-2-yl)-6-trifluoromethyl-pyrimidin-2-yl]-phenyl}- thiophene-2-sulfonic acid tert-butylamide was prepared from 2-(3-bromo-phenyl)-4-(5- chloro-thiophen-2-yl)-6-trifluoromethyl-pyrimidine (example B.3) (0.31 g, 0.74 mmol) and N-tert-butyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-thiophene-2- sulfonamide (example Cl) (0.28 g, 0.81 mmol) according to the general procedure III. Obtained as light yellow oil (0.23 g), which was subsequently deprotected. 2) To a cooled and stirred solution of 5-{3-[4-(5-chloro-thiophen-2-yl)-6- trifluoromethyl-pyrimidin-2-yl] -phenyl} -thiophene-2-sulfonic acid tert-butylamide (0.23 g) in dichloromethane (5 ml) was added TFA (5 ml) and the reaction mixture was allowed to stir at room temperature for 15 h. The mixture was evaporated, and purified by flash chromatography on silica gel (ethyl acetate/ heptane) and crystallization (MeOH, dichloromethane, hexane) yielded the title compound as a light yellow solid (0.084 g, 23%). MS (ISP) 502.0 [(MH-H)+]; mp 233 0C. Example 8
4-[4-Trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yll- [2,3'lbipyridinyl-6'-ylamine The title compound was prepared from 2-(2-chloro-pyridin-4-yl)-4-trifluoromethyl-6- (6-trifluoromethyl-pyridin-3-yl)-pyrimidine (example B.4) (0.2 g, 0.5 mmol) and commercially available 2-amino-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (0.13 g, 0.6 mmol) according to the general procedure III. Obtained as a yellow solid (0.1 g, 43%). MS (ISP) 463.1 [(M+H)+]; mp 261.5 0C.
Example 9
3-{4-[4-Trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yll-pyridin-2- yl}-benzenesulfonamide 1) 3-{4-[4-Trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]-pyridin- 2-yl}-benzenesulfonic acid tert-butylamide was prepared from 2-(2-chloro-pyridin-4-yl)- 4-trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidine (example B.4) (0.81 g, 2.0 mmol) and commercially available 3-(tert.-butylsulfamoyl)-phenylboronic acid (0.62 g, 2.4 mmol) according to the general procedure III. Obtained as off-white solid (0.71 g), which was subsequently deprotected. 2) To a cooled and stirred solution of 3-{4-[4-trifluoromethyl-6-(6-trifluoromethyl- pyridin-3-yl)-pyrimidin-2-yl]-pyridin-2-yl}-benzenesulfonic acid tert-butylamide (0.71 g) in dichloromethane (12 ml) was added TFA (12 ml) and the reaction mixture was allowed to stir at room temperature for 15 h. The mixture was evaporated to dryness, poured into 2N Na2CO3 solution (25 ml) and extracted with ethyl acetate (3 x 50 ml). The combined organic layers were washed with brine (50 ml), dried (MgSO/O and evaporated. Further purification by crystallization (ethyl acetate/ heptane) yielded the title compound as a white solid (0.51 g, 49%). MS (ISP) 526.2 [(M+H)+]; mp 258 0C.
Example 10 5-{4-[4-Trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yll-pyridin-2- yl}-thiophene-2-sulfonic acid amide
1) 5-{4-[4-Trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]-pyridin- 2-yl}-thiophene-2-sulfonic_acid tert-butylamide was prepared from 2-(2-chloro-pyridin- 4-yl)-4-trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidine (example B.4) (0.405 g, 1.0 mmol) and N-tert-butyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)- thiophene-2-sulfonamide (example Cl) (0.414 g, 1.2 mmol) according to the general procedure III. Obtained as an off-white solid (0.44 g), which was subsequently deprotected.
2) To a cooled and stirred solution of 5-{4-[4-trifluoromethyl-6-(6-trifluoromethyl- pyridin-3-yl)-pyrimidin-2-yl]-pyridin-2-yl}-thiophene-2-sulfonic_acid tert-butylamide (0.44 g) in dichloromethane (6 ml) was added TFA (6 ml) and the reaction mixture was allowed to stir at room temperature for 15 h. The mixture was evaporated to dryness, poured into 2N Na2CO3 solution (25 ml) and extracted with ethyl acetate (3 x 50 ml). The combined organic layers were washed with brine (50 ml), dried (MgSO/O and evaporated. Further purification by flash chromatography on silica gel (ethyl acetate/ heptane) and crystallization (MeOH, dichloromethane) yielded the title compound as a white solid (0.11 g, 21%). MS (ISP) 532.0 [(M+H)+]; mp 262.5 0C.
Example 11
N-Propionyl-3-{4-[4-trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2- yll-pyridin-2-yl}-benzenesulfonamide
A mixture of 3-{4- [4-trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2- yl]-pyridin-2-yl}-benzenesulfonamide (example 9) (0.3 g, 0.57 mmol) and propionic acid anhydride (0.75 ml) was stirred at 1600C for 29 h. Hexane (15 ml) was added drop wise to the mixture at a temperature of 800C while the product precipitated. Ethyl acetate (2 ml) was added and the mixture was allowed to stir at RT for Ih. The precipitate was collected by filtration and dried to yield the title compound (0.23 g, 69%) as a white solid. MS (ISP) 582.1 [(M+H)+]; mp 242 0C.
Example 12 5-{3-[4-Trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yll -phenyl}- pyridin - 2 -ylamine
The title compound was prepared from 2-(3-bromo-phenyl)-4-trifluoromethyl-6-(6- trifluoromethyl-pyridin-3-yl)-pyrimidine (example B.2) (0.22 g, 0.5 mmol) and commercially available 2-amino-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (0.13 g, 0.6 mmol) according to the general procedure III. Obtained as a yellow solid (0.2 g, 87%). MS (ISP) 462.2 [(M+H)+]; mp 244 0C.
Example 13
5-{ l-[4-Trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yll-lH- imidazol-4-yl}-pyridin-2-ylamine
The title compound was prepared from 2-(4-iodo-imidazol-l-yl)-4-trifluoromethyl-6-(6- trifluoromethyl-pyridin-3-yl)-pyrimidine (example B.5) (0.485 g, 1.0 mmol) and commercially available 2-amino-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (0.264 g, 1.2 mmol) according to the general procedure III. Obtained as a yellow solid (0.03 g, 7%). MS (ISP) 452.1 [(M+H)+]; mp 259 0C.
Example 14
5-{ l-[4-Difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yll-lH- imidazol-4-yl}-pyridin-2-ylamine
The title compound was prepared from 2-(4-iodo-imidazol-l-yl)-4-difluoromethyl-6-(6- trifluoromethyl-pyridin-3-yl)-pyrimidine (example B.8) (0.47 g, 1.0 mmol) and commercially available 2-amino-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (0.264 g, 1.2 mmol) according to the general procedure III. Obtained as a yellow solid (0.066 g, 15%). MS (ISP) 434.2 [(MH-H)+]; mp 258 0C.
Example 15 3'-[4-Difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yll-biphenyl-3- sulfonic acid amide
1) 3'-[4-Difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]-biphenyl-3- sulfonic acid tert-butylamide was prepared from 2-(3-bromo-phenyl)-4-difluoromethyl- 6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidine (example B.6) (0.43 g, 1.0 mmol) and commercially available 3-(tert.-butylsulfamoyl)-phenylboronic acid (0.31 g, 1.2 mmol) according to the general procedure III. Obtained as light yellow solid (0.62 g), which was subsequently deprotected.
2) To a cooled and stirred solution of 3'-[4-difluoromethyl-6-(6-trifluoromethyl- pyridin-3-yl)-pyrimidin-2-yl]-biphenyl-3-sulfonic acid tert-butylamide (0.56 g) in dichloromethane (7 ml) was added TFA (7 ml) and the reaction mixture was allowed to stir at room temperature for 15 h. The mixture was evaporated to dryness, poured into 2N Na2CO3 solution (25 ml) and extracted with ethyl acetate (3 x 50 ml). The combined organic layers were washed with brine (50 ml), dried (MgSO/0 and evaporated. Further purification by crystallization (ethyl acetate/ heptane) yielded the title compound as a white solid (0.41 g, 81%). MS (ISP) 507.2 [(MH-H)+] ; mp 222 0C.
Example 16
3-{4-[4-Difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]-pyridin-2- yl}-benzenesulfonamide 1) 3-{4-[4-Difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]-pyridin- 2-yl}-benzenesulfonic acid tert-butylamide was prepared from 2-(2-chloro-pyridin-4-yl)- 4-difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidine (example B.7) (0.19 g, 0.5 mmol) and commercially available 3-(tert.-butylsulfamoyl)-phenylboronic acid (0.15 g, 0.6 mmol) according to the general procedure III. Obtained as off-white solid (0.16 g), which was subsequently deprotected.
2) To a cooled and stirred solution of 3-{4-[4-difluoromethyl-6-(6-trifluoromethyl- pyridin-3-yl)-pyrimidin-2-yl]-pyridin-2-yl}-benzenesulfonic acid tert-butylamide (0.16 g) in dichloromethane (4 ml) was added TFA (4 ml) and the reaction mixture was allowed to stir at room temperature for 15 h. The mixture was evaporated to dryness, poured into 2N Na2CO3 solution (25 ml) and extracted with ethyl acetate (3 x 50 ml). The combined organic layers were washed with brine (50 ml), dried (MgSO4) and evaporated. Further purification by column chromatography on silica gel (dichloromethane/ MeOH/ NH4OH 16:1:0.1) and trituration (diethyl ether) yielded the title compound as a white solid (0.056 g, 22%). MS (ISP) 508.1 [(M+H)+]; mp 264.5 0C.
Example 17 5-{4-[4-Difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yll-pyridin-2- yl}-thiophene-2-sulfonic acid amide
1) 5-{4-[4-Difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]-pyridin- 2-yl}-thiophene-2-sulfonic_acid tert-butylamide was prepared from 2-(2-chloro-pyridin- 4-yl)-4-difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidine (example B.7) (0.39 g, 1.0 mmol) and N-tert-butyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)- thiophene-2-sulfonamide (example Cl) (0.414 g, 1.2 mmol) according to the general procedure III. Obtained as an off-white solid (0.36 g), which was subsequently deprotected.
2) To a cooled and stirred solution of 5-{4-[4-difluoromethyl-6-(6-trifluoromethyl- pyridin-3-yl)-pyrimidin-2-yl] -pyridin-2-yl}-thiophene-2-sulfonic_acid tert-butylamide (0.36 g) in dichloromethane (6 ml) was added TFA (6 ml) and the reaction mixture was allowed to stir at room temperature for 15 h. The mixture was evaporated to dryness, poured into 2N Na2CO3 solution (25 ml) and extracted with ethyl acetate (3 x 50 ml). The combined organic layers were washed with brine (50 ml), dried (MgSO4) and evaporated. Further purification by flash chromatography on silica gel (ethyl acetate/ heptane) and crystallization (MeOH, dichloromethane) yielded the title compound as a white solid (0.11 g, 21%). MS (ISP) 514.2 [(MH-H)+]; mp 269.5 0C.
Example 18 5-{3-[4-Difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yll-phenyl}- thiophene-2-sulfonic acid amide 1) N-tert-Butyl-5-{3-[4-difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2- yl] -phenyl} -thiophene-2-sulfonic acid amide was prepared from 2-(3-bromo-phenyl)-4- difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidine (example B.6) (0.43 g, 1.0 mmol) and N-tert-butyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-thiophene-2- sulfonamide (example Cl) (0.414 g, 1.2 mmol) according to the general procedure III. Obtained as an off-white solid (0.46 g), which was subsequently deprotected.
2) To a cooled and stirred solution of N-tert-butyl-5-{3-[4-difluoromethyl-6-(6- trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl] -phenyl} -thiophene-2-sulfonic acid amide (0.46 g) in dichloromethane (7 ml) was added TFA (7 ml) and the reaction mixture was allowed to stir at room temperature for 15 h. The mixture was evaporated to dryness, poured into 2N Na2CO3 solution (25 ml) and extracted with ethyl acetate (3 x 50 ml). The combined organic layers were washed with brine (50 ml), dried (MgSO4) and evaporated. Further purification by flash chromatography on silica gel (ethyl acetate/ heptane) and crystallization (dichloromethane/ MeOH) yielded the title compound as a white solid (0.16 g, 31%). MS (ISP) 513.2 [(MH-H)+] ; mp 245.5 0C.
Example 19
3-{ l-[4-Difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yll-lH- imidazol-4-yl}-benzenesulfonamide 1) 3-{ l-[4-Difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]-lH- imidazol-4-yl}-benzenesulfonic acid tert-butylamide was prepared from 2-(4-iodo- imidazol-l-yl)-4-difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidine (example B.8) (0.47 g, 1.0 mmol) and commercially available 3-(tert.-butylsulfamoyl)- phenylboronic acid (0.31 g, 1.2 mmol) according to the general procedure III. Obtained as light yellow solid (0.06 g), which was subsequently deprotected.
2) To a cooled and stirred solution of 3-{ l-[4-difluoromethyl-6-(6-trifluoromethyl- pyridin-3-yl)-pyrimidin-2-yl]-lH-imidazol-4-yl}-benzenesulfonic acid tert-butylamide (0.06 g) in dichloromethane (2 ml) was added TFA (2 ml) and the reaction mixture was allowed to stir at room temperature for 15 h. The mixture was evaporated to dryness, poured into 2N Na2CO3 solution (25 ml) and extracted with ethyl acetate (3 x 50 ml). The combined organic layers were washed with brine (50 ml), dried (MgSO4) and evaporated. Further purification by column chromatography on silica gel (dichloromethane/ MeOH/ NH4OH 16:1:0.1) and crystallization (diethyl ether) yielded the title compound as a white solid (0.022 g, 4%). MS (ISP) 497.2 [(MH-H)+]; mp 219.5 0C. Example 20
5-{ l-[4-Methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yll-lH-imidazol-4-yl}- pyridin - 2 -ylamine
The title compound was prepared from 2-(4-iodo-imidazol-l-yl)-4-methyl-6-(6- trifluoromethyl-pyridin-3-yl)-pyrimidine (example B.9) (0.35 g, 0.81 mmol) and commercially available 2-amino-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (0.214 g, 0.97 mmol) according to the general procedure III. Obtained as a yellow solid (0.19 g, 59%). MS (ISP) 398.2 [(M+H)+]; mp 220 0C.
Example 21
3-{4-[4-Methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yll-pyridin-2-yl}- benzenesulfonamide
1) 3-{4-[4-Methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]-pyridin-2-yl}- benzenesulfonic acid tert-butylamide was prepared from 2-(2-chloro-pyridin-4-yl)-4- methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidine (example B.10) (0.175 g, 0.5 mmol) and commercially available 3-(tert.-butylsulfamoyl)-phenylboronic acid (0.15 g, 0.6 mmol) according to the general procedure III. Obtained as off-white solid (0.08 g), which was subsequently deprotected.
2) To a cooled and stirred solution of 3-{4-[4-methyl-6-(6-trifluoromethyl-pyridin-3- yl)-pyrimidin-2-yl]-pyridin-2-yl}-benzenesulfonic acid tert-butylamide (0.08 g) in dichloromethane (2 ml) was added TFA (2 ml) and the reaction mixture was allowed to stir at room temperature for 15 h. The mixture was evaporated to dryness, poured into 2N Na2CO3 solution (20 ml) and extracted with ethyl acetate (3 x 50 ml). The combined organic layers were washed with brine (50 ml), dried (MgSO/O and evaporated. Further purification by crystallization (ethyl acetate/ heptane) yielded the title compound as a white solid (0.036 g, 15%). MS (ISP) 472.2 [(M+H)+]; mp 255 0C.
Example 22 5-{4-[4-Methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yll-pyridin-2-yl}- thiophene-2-sulfonic acid amide
1) 5-{4-[4-Difluoromethyl-6-(6-methyl-pyridin-3-yl)-pyrimidin-2-yl]-pyridin-2-yl}- thiophene-2-sulfonic_acid tert-butylamide was prepared from 2-(2-chloro-pyridin-4-yl)- 4-methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidine (example B.10) (0.175 g, 0.5 mmol) and N-tert-butyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-thiophene-2- sulfonamide (example Cl) (0.21 g, 0.6 mmol) according to the general procedure III. Obtained as an off-white solid (0.11 g), which was subsequently deprotected. 2) To a cooled and stirred solution of 5-{4-[4-methyl-6-(6-trifluoromethyl-pyridin-3-yl)- pyrimidin-2-yl]-pyridin-2-yl}-thiophene-2-sulfonic_acid tert-butylamide (0.11 g) in dichloromethane (3 ml) was added TFA (3 ml) and the reaction mixture was allowed to stir at room temperature for 15 h. The mixture was evaporated to dryness, poured into 2N Na2CO3 solution (20 ml) and extracted with ethyl acetate (3 x 50 ml). The combined organic layers were washed with brine (50 ml), dried (MgSO4) and evaporated. Further purification by column chromatography on silica gel (dichloromethane/ MeOH/ NH4OH 16:1:0.1) and crystallization (MeOH, diethyl ether) yielded the title compound as a white solid (0.016 g, 7%). MS (ISP) 478.1 [(M+H)+]; mp 289 0C.
Example 23
3'-[4-Methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yll-biphenyl-3-sulfonic acid amide 1) 3'-[4-Methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]-biphenyl-3-sulfonic acid tert-butylamide was prepared from 2-(3-bromo-phenyl)-4-methyl-6-(6- trifluoromethyl-pyridin-3-yl)-pyrimidine (example B.I 1) (0.197 g, 0.5 mmol) and commercially available 3-(tert.-butylsulfamoyl)-phenylboronic acid (0.15 g, 0.6 mmol) according to the general procedure III. Obtained as light yellow solid (0.24 g), which was subsequently deprotected. 2) To a cooled and stirred solution of 3'-[4-methyl-6-(6-trifluoromethyl-pyridin-3-yl)- pyrimidin-2-yl]-biphenyl-3-sulfonic acid tert-butylamide (0.24 g) in dichloromethane (6 ml) was added TFA (6 ml) and the reaction mixture was allowed to stir at room temperature for 15 h. The mixture was evaporated to dryness, poured into 2N Na2CO3 solution (25 ml) and extracted with ethyl acetate (3 x 50 ml). The combined organic layers were washed with brine (50 ml), dried (MgSO4) and evaporated. Further purification by crystallization (ethyl acetate/ heptane) yielded the title compound as a white solid (0.081 g, 34%). MS (ISP) 471.2 [(M+H)+]; mp 220 0C.
Example 24 5-{3-[4-Methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yll-phenyl}-thiophene- 2 -sulfonic acid amide
1) N-tert-Butyl-5-{3- [4-methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl] - phenyl} -thiophene-2-sulfonic acid amide was prepared from 2-(3-bromo-phenyl)-4- methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidine (example B.I 1) (0.197 g, 0.5 mmol) and N-tert-butyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-thiophene-2- sulfonamide (example Cl) (0.21 g, 0.6 mmol) according to the general procedure III. Obtained as an off-white solid (0.1 g), which was subsequently deprotected. 2) To a cooled and stirred solution of N-tert-butyl-5-{3-[4-methyl-6-(6-trifluoromethyl- pyridin-3-yl)-pyrimidin-2-yl]-phenyl}-thiophene-2-sulfonic acid amide (0.1 g) in dichloromethane (4 ml) was added TFA (4 ml) and the reaction mixture was allowed to stir at room temperature for 15 h. The mixture was evaporated to dryness, poured into 2N Na2CO3 solution (25 ml) and extracted with ethyl acetate (3 x 50 ml). The combined organic layers were washed with brine (50 ml), dried (MgSO4) and evaporated. Further purification by column chromatography on silica gel (dichloromethane/ MeOH/ NH4OH 16:1:0.1) and crystallization (diethyl ether/ MeOH) yielded the title compound as a white solid (6 mg, 3%). MS (ISP) 477.1 [(M+H)+]; mp 237.5 0C.
Example 25
N-tert-Butyl-3-{6-[4-methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yll- pyridin - 2 -yl } -benzenesulfonamide Prepared according to the general procedure IV: 3-Aryl-2-alkyne-l-one part:
1) 4-(5-Trifluoromethyl-pyridin-2-yl)-but-3-yn-2-ol: Commercially available 5-bromo- 2-(trifluoromethyl)pyridine [CAS-no. 436799-32-5] (1.0 g, 4.44 mmol), commercially available 3-butyn-2-ol [CAS-no. 2028-63-9] (0.49 ml, 6.66 mmol), triethylamine (1.23 ml, 8.88 mmol), Pd(PPh3)2Cl2 (31 mg, 1 mol%) and triphenylphosphine (23 mg, 2 mol%) were dissolved in THF (15 ml), argon was bubbled through the suspension for 20 minutes, then copper(I) iodide (8 mg, 1 mol%) was added and the mixture was stirred at 80 0C for 12 h. The reaction mixture was poured onto water, then extracted three times with ethyl acetate, the combined organic layers were dried over MgSO4, filtered and the solvents evaporated to give the crude product (4 g) as a brown liquid, which was purified by flash chromatography with n-heptane and ethyl acetate to give the 4-(5- trifluoromethyl-pyridin-2-yl)-but-3-yn-2-ol as a brown liquid (0.915 g, 96%). MS (ISP) 216.2 [(M+H)+].
2) 4-(5-Trifluoromethyl-pyridin-2-yl)-but-3-yn-2-one: The above described 4-(5- trifluoromethyl-pyridin-2-yl)-but-3-yn-2-ol (0.885 g, 4.1 mmol) was dissolved in methylene chloride (20 ml), cooled to 0 0C, then Dess-Martin periodinane (1.88 g, 4.32 mmol) was added and the mixture was stirred at 0 0C for 2 h. To the reaction mixture was added diethyl ether, the precipitate filtered off, washed with diethyl ether, the filtrate was extracted with diethyl ether and saturated NaHCθ3-sol., the organic layers were dried over MgSO4, filtered and the solvents were evaporated to give the 4-(5-trifluoromethyl- pyridin-2-yl)-but-3-yn-2-one as a brown solid (0.888 g, 100%), which was used without further purification. MS (EI) 213.1 [M+]. Amidine part:
1) 3-(6-Bromo-pyridin-2-yl)-N-tert-butyl-benzenesulfonamide: A mixture of commercially available 3-(tert-butylsulfamoyl)-benzeneboronic acid [CAS-no. 221290- 14-8] (5.142 g, 20 mmol), commercially available 2,6-dibromopyridine (14.2 g, 60 mmol) and Pd(PPh3)4 (1.156 g, 5 mol%) in DME (80 ml) and aqueous sodium carbonate (1 M, 40 ml, 40 mmol) was stirred at 90 0C under argon atmosphere for 18 h. The reaction mixture was extracted with water and ethyl acetate, the organic layers dried over MgSO4, filtered and the solvents evaporated. The crude product was purified by flash chromatography with n-heptane/ethyl acetate to give the 3-(6-bromo-pyridin-2-yl)-N- tert-butyl-benzenesulfonamide (6.60 g, 89%) as a yellow solid. MS (ISP) 369.1 [(M+H)+] and 371.0 [(M+2+H)+].
2) N-tert-Butyl-3-(6-cyano-pyridin-2-yl)-benzenesulfonamide: A mixture of the above described 3-(6-bromo-pyridin-2-yl)-N-tert-butyl-benzenesulfonamide (3.12 g, 8 mmol) and copper(I) cyanide (1.6 g, 18 mmol) in NMP (15 ml) was stirred at 120 0C for 1 h. Cooled to rt, the reaction mixture was extracted with aqueous ammonia and ethyl acetate, the organic layers were dried over MgSO4, filtered and the solvents were evaporated. The crude product was purified by flash chromatography with n-heptane and ethyl acetate to give the N-tert-butyl-3-(6-cyano-pyridin-2-yl)-benzenesulfonamide (1.05 g, 39%) as a light brown oil. MS (ISP) 316.1 [(M+H)+]. 3) 6-(3-tert-Butylsulfamoyl-phenyl)-N-hydroxy-pyridine-2-carboxamidine: A mixture of the above described N-tert-butyl-3-(6-cyano-pyridin-2-yl)-benzenesulfonamide (1.03 g, 3.27 mmol), hydroxylamine hydrochloride (794 mg, 11.4 mmol) and sodium carbonate (692 mg, 6.53 mmol) in EtOH (20 ml) and water (20 ml) was stirred under argon atmosphere at 100 0C for 2 h. The EtOH was evaporated, the mixture was diluted with water and stirred for 1 h at 0 0C. The crude product was filtered and dried in HV to give the pure 6-(3-tert-butylsulfamoyl-phenyl)-N-hydroxy-pyridine-2-carboxamidine as a white solid (850 mg, 75%). MS (ISP) 349.3 [(M+H)+].
4) 6-(3-tert-Butylsulfamoyl-phenyl)-pyridine-2-carboxamidinium acetate: To a mixture of the above described 6-(3-tert-butylsulfamoyl-phenyl)-N-hydroxy-pyridine-2- carboxamidine (Example C.7) (830 mg, 2.38 mmol) in acetic acid (10 ml) at 23 0C was added acetic anhydride (0.34 ml, 3.57 mmol) and the mixture was stirred at 23 0C for 10 min, then 10% Pd on charcoal (84 mg, 0.79 mmol) was added and the mixture was hydrogenated ( 1 bar hydrogen) at 23 0C for 24 h. The catalyst was filtered off, washed with acetic acid and the solvents were evaporated to give the 6-(3-tert-butylsulfamoyl- phenyl) -pyridine-2-carboxamidinium acetate (1.38 g, 148%, contains excess acetic acid) as a light yellow oil, which was used without further purification (cf. Synth. Commun. 1996, 26(23), 4351). MS (ISP) 333.1 [(M+H)+]. Condensation reaction: The above described 4-(5-trifluoromethyl-pyridin-2-yl)-but-3- yn-2-one (53 mg, 0.25 mmol), the also above described 6-(3-tert-butylsulfamoyl- phenyl)-pyridine-2-carboxamidinium acetate (118 mg, 0.3 mmol) and sodium carbonate (64 mg, 0.6 mmol) were dissolved in acetonitrile (2 ml) and treated by microwave irradiation at 120 0C for 60 min. The reaction mixture was extracted with ethyl acetate and water, the organic layers were combined, dried over MgSCU, filtered and the solvents were evaporated to give a crude product, which was purified by flash chromatography with n-heptane and ethyl acetate to give the title compound as a light brown foam (63 mg, 48%). MS (ISP) 528.2 [(M+H)+].
Example 26
N-tert-Butyl-3-{6-[4-methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yll- pyridin - 2 -yl } -benzenesulfonamide Prepared according to the general procedure IV: 3-Aryl-2-alkyne-l-one part:
1) 4-(6-Trifluoromethyl-pyridin-3-yl)-but-3-yn-2-ol: Commercially available 2-bromo- 5-(trifluoromethyl)pyridine [CAS-no. 50488-42-1] (3.33 g, 14.7 mmol), commercially available 3-butyn-2-ol [CAS-no. 2028-63-9] (1.63 ml, 22.2 mmol), triethylamine (6.2 ml, 29.5 mmol), Pd(PPh3)2Cl2 (104 mg, 1 mol%) and triphenylphosphine (77 mg, 2 mol%) were dissolved in THF (50 ml), argon was bubbled through the suspension for 20 minutes, then copper(I) iodide (28 mg, 1 mol%) was added and the mixture was stirred at 80 0C for 12 h. The reaction mixture was poured onto water, then extracted three times with ethyl acetate, the combined organic layers were dried over MgSCU, filtered and the solvents evaporated to give the crude product (4 g) as a brown liquid, which was purified by flash chromatography with n-heptane and ethyl acetate to give the 4-(6- trifluoromethyl-pyridin-3-yl)-but-3-yn-2-ol as a brown liquid (1.60 g, 50%). MS (ISP) 216.3 [(M+H)+].
2) 4-(6-Trifluoromethyl-pyridin-3-yl)-but-3-yn-2-one: The above prepared 4-(6- trifluoromethyl-pyridin-3-yl)-but-3-yn-2-ol (1.60 g, 7 mmol) was dissolved in methylene chloride (40 ml), cooled to 0 0C, then Dess-Martin periodinane (3.41 g, 8 mmol) was added and the mixture was stirred at 0 0C for 2 h. To the reaction mixture was added diethyl ether, the precipitate filtered off, washed with diethyl ether, the filtrate was extracted with diethyl ether and saturated NaHCθ3-sol., the organic layers were dried over MgSCU, filtered and the solvents were evaporated to give the 4-(6-trifluoromethyl- pyridin-3-yl)-but-3-yn-2-one as a brown solid (1.59 g, 100%), which was used without further purification. MS (EI) 213.1 [M+]. Condensation reaction: The above described 4-(6-trifluoromethyl-pyridin-3-yl)-but-3- yn-2-one (53 mg, 0.25 mmol), 6-(3-tert-butylsulfamoyl-phenyl)-pyridine-2- carboxamidinium acetate (Example 26, amidine part, steps 1 to 4) (118 mg, 0.3 mmol) and sodium carbonate (64 mg, 0.6 mmol) were dissolved in acetonitrile (2 ml) and treated by microwave irradiation at 120 0C for 60 min. The reaction mixture was extracted with ethyl acetate and water, the organic layers were combined, dried over MgSO/t, filtered and the solvents were evaporated to give a crude product, which was purified by flash chromatography with n-heptane and ethyl acetate to give the title compound as a light brown foam (100 mg, 76%). MS (ISP) 528.2 [(M+H)+].
Example 27
3-{6-[4-Methyl-6-(5-trifluoromethyl-pyridin-2-yl)-pyrimidin-2-yll-pyridin-2-yl}- benzenesulfonamide
To N-tert-butyl-3-{6- [4-methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl] - pyridin-2-yl}-benzenesulfonamide (Example 25) (0.056 g, 0.106 mmol) was added TFA (2 mL) and the reaction mixture was stirred at 23 0C for 16 h. The mixture was partitioned between EtOAc and saturated NaHCθ3 solution, the organic layer was dried over Na2SO4. Removal of the solvent in vacuum left a crude product which was triturated with diethyl ether to give the title compound as an off-white solid (0.050 g, 100%). MS (ISP) 471.9 [(M+H)+]; mp 246-252 0C.
Example 28
3-{6-[4-Methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yll-pyridin-2-yl}- benzenesulfonamide
To N-tert-butyl-3-{6- [4-methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl] - pyridin-2-yl} -benzenesulfonamide (Example 26) (0.092 g, 0.174 mmol) was added TFA (2 mL) and the reaction mixture was stirred at 23 0C for 16 h. The mixture was partitioned between EtOAc and saturated NaHCθ3 solution, the organic layer was dried over Na2SO/t. Removal of the solvent in vacuum left a crude product which was triturated with diethyl ether to give the title compound as an off-white solid (0.080 g, 98%). MS (ISP) 472.0 [(M+H)+]; mp 254 0C. Example 29
N-tert-Butyl-3-(6'-methyl-6"-trifluoromethyl-[2,2';4',3"1terpyridin-6-yl)- benzenesulfonamide
A stirred mixture of trifluoro-methanesulfonic acid 6'-methyl-6-trifluoromethyl- [3,4']bipyridinyl-2'-yl ester (Example A.5) (0.193 g, 0.5 mmol), N-tert-butyl-3-(6- tributylstannanyl-pyridin-2-yl)-benzenesulfonamide (Example C.2) (0.264 g, 0.455 mmol), tetrakis(triphenyl-phosphine)palladium (0.029 g, 5 mol%) in toluene (5 mL) was heated under reflux conditions forl8 h. Cooled to rt, extracted with ethyl acetate and water, dried the organic layer over Na2SO4. Removal of the solvent in vacuum left a crude product which was purified by silica gel column chromatography with n- heptane/ ethyl acetae to give the title compound after trituration with diethyl ether as a white solid (110 mg, 42%). MS (ISP) 527.0 [(M+H)+]; mp 187-188 0C.
Example 30
3-(6'-Methyl-6"-trifluoromethyl-[2,2';4',3"1terpyridin-6-yl)-benzenesulfonamide
To N-tert-butyl-3-(6'-methyl-6"-trifluoromethyl-[2,2';4',3"]terpyridin-6-yl)- benzenesulfonamide (Example 29) (0.075 g, 0.142 mmol) was added TFA (2 mL) and the reaction mixture was stirred at 23 0C for 16 h. The mixture was partitioned between EtOAc and saturated NaHCθ3 solution, the organic layer was dried over Na2SO4. Removal of the solvent in vacuum left a crude product which was triturated with diethyl ether to give the title compound as an off-white solid (0.032 g, 48%). MS (ISP) 471.0 [(M+H)+]; mp 233-234 0C.
Example 31
3'-(6'-Methyl-6-trifluoromethyl- [3,4'lbipyridinyl-2'-yl)-biphenyl-3-sulfonic acid tert- butylamide
The title compound was prepared from 6'-(3-bromo-phenyl)-2'-methyl-6- trifluoromethyl-[3,4']bipyridinyl (example B.12) (0.197 g, 0.5 mmol) and commercially available 3-(tert-butylsulfamoyl)-benzeneboronic acid (0.142 g, 0.55 mmol) according to the general procedure III. Obtained as a white foam (0.245 g, 93%). MS (ISP) 526.7 [(M+H)+].
Example 32
5- [3-(6'-Methyl-6-trifluoromethyl- [3,4']bipyridinyl-2'-yl)-phenyl] -pyridin-2-ylamine
The title compound was prepared from 6'-(3-bromo-phenyl)-2'-methyl-6- trifluoromethyl-[3,4']bipyridinyl (example B.12) (0.197 g, 0.5 mmol) and N-tert-butyl-5- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-thiophene-2-sulfonamide (example Cl) (0.190 g, 0.55 mmol) according to the general procedure III. Obtained as a white foam (0.130 g, 49%). MS (ISP) 532.6 [(M+H)+].
Example 33
5- [3-(6'-Methyl-6-trifluoromethyl- [3,4']bipyridinyl-2'-yl)-phenyl] -pyridin-2-ylamine
The title compound was prepared from 6'-(3-bromo-phenyl)-2'-methyl-6- trifluoromethyl-[3,4']bipyridinyl (example B.12) (0.098 g, 0.25 mmol) and commercially available 2-amino-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (0.61 g, 0.275 mmol) according to the general procedure III. Obtained as an off- white solid (0.031 g, 31%). MS (ISP) 407.3 [(M+H)+]; mp 124-125 0C.
Example 34
3'-(6'-Methyl-6-trifluoromethyl- [3,4'1bipyridinyl-2'-yl)-biphenyl-3-sulfonic acid amide
To 3'-(6'-methyl-6-trifluoromethyl-[3,4']bipyridinyl-2'-yl)-biphenyl-3-sulfonic acid tert- butylamide (Example 31) (0.150 g, 0.285 mmol) was added TFA (2 mL) and the reaction mixture was stirred at 23 0C for 16 h. The mixture was partitioned between EtOAc and saturated NaHCθ3 solution, the organic layer was dried over Na2SO/t. Removal of the solvent in vacuum left a crude product which was triturated with diethyl ether to give the title compound as a white solid (0.090 g, 75%). MS (ISP) 470.1 [(M+H)+]; mp 227-232 0C. Example 35
5- [3-(6'-Methyl-6-trifluoromethyl- [3,4'lbipyridinyl-2'-yl)-phenyll -thiophene-2-sulfonic acid amide
To 5- [3-(6'-methyl-6-trifluoromethyl- [3,4']bipyridinyl-2'-yl)-phenyl] -pyridin-2-ylamine (Example 32) (0.100 g, 0.188 mmol) was added TFA (2 mL) and the reaction mixture was stirred at 23 0C for 16 h. The mixture was partitioned between EtOAc and saturated NaHCθ3 solution, the organic layer was dried over Na2SO4. Removal of the solvent in vacuum left a crude product which was triturated with diethyl ether to give the title compound as a white solid (0.090 g, 100%). MS (ISP) 476.8 [(M+H)+]; mp 231-233 0C.

Claims

Claims
1. A compound of formula (I):
wherein either one of X or Y is N and the other is CH, or both X and Y are N; Q is S, O, -CH=N- or -N=CH-; A is aryl or 5 or 6 membered heteroaryl each of which is optionally substituted by C1- 6-alkyl;
B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituents are selected from the group consisting of: halo, nitro,
Ci-6-alkyl optionally substituted by hydroxy,
NRaRb, wherein Ra and Rb are independently H, C1-6-alkyl or -(CO)-C1-6- alkyl,
-S-Ci-6-alkyl, -(SO2)-OH, -(SO2)-C1-6-alkyl,
-(SO2)-NRcRd, wherein Rc and Rd are independently: H,
Ci-6-alkyl optionally substituted by hydroxy, Ci-6-haloalkyl, Ci-6-alkoxy,
-(CO)Ci-6-alkyl optionally substituted by Ci-6-alkoxy, -(CH2CH2O)nCHR6, wherein Re is H or CH2OH and n is 1, 2, 3, 4, 5, 6,
7, 8, 9 or 10,
-(CH2)m-aryl, wherein m is 1 or 2 and the aryl is optionally substituted by halo or Ci-6-alkoxy, -(CH2)p-C3-6-cycloalkyl, wherein p is 0 or 1, 5 or 6-membered heterocycloalkyl,
-(Sθ2)-NRfRg, wherein Rf and Rg together with the nitrogen atom to which they are attached form a 4, 5 or 6 membered heterocycloalkyl ring optionally containing a further heteroatom selected from nitrogen, oxygen, sulphur or a SO2 group, wherein said 4, 5 or 6 membered heterocycloalkyl ring is optionally substituted by a substituent selected from the group consisting of: hydroxy, Ci-6-alkyl, Ci-6-alkoxy which is optionally substituted by hydroxy, and 5 or 6 membered heteroaryloxy, NHSO2-Ci-6-alkyl, NHSO2-NR11R1 wherein Rh and R1 are independently H, Ci-6-alkyl, -(CO)O-
Ci-6-alkyl, or Rh and R1 together with the nitrogen atom to which they are attached form a 4, 5 or 6 membered heterocycloalkyl ring optionally containing a further heteroatom selected from nitrogen, oxygen or sulphur, wherein said 4, 5 or 6 membered heterocycloalkyl ring is optionally substituted by Q-6-alkyl,
R1 is H, halogen, Ci-6-alkyl optionally substituted by hydroxy, Ci-6-alkoxy, C1-6- haloalkyl, C3-6-cycloalkyl; R2 is selected from the group consisting of: cyano, halogen, Ci-6-haloalkyl, Ci-6-alkoxy,
Ci-6-haloalkoxy, Ci-6-alkyl and C3-6-cycloalkyl; or is NRJRk wherein R and Rk are independently selected from the group consisting of:
H, C3-8-cycloalkyl, aryl, heteroaryl having from 5 to 12 ring atoms and C1-6- alkyl which optionally substituted by one or more substituent(s) selected from the group consisting of halogen, hydroxy, C3-8-cycloalkyl, aryl, heteroaryl having from 5 to 12 ring atoms and -NR1R111, wherein R1 and R111 are independently selected from the group consisting of H and Ci-6-alkyl; or R1 and R111 can, together with the nitrogen atom to which they are attached, form an optionally substituted heterocyclic group comprising 5 to 12 ring atoms optionally containing a further heteroatom selected from nitrogen, oxygen or sulphur, wherein said heterocyclic group is optionally substituted by one, two, three, four or five substituents are selected from the group consisting of halogen, hydroxy, Ci-6-alkyl and Ci-6-haloalkyl; as well as pharmaceutically acceptable salts thereof.
2. The compound of formula (I) according to claim 1, wherein: both X and Y are N or X is N and Y is CH; Q is S, -CH=N-, or -N=CH-; A is aryl or 5 or 6 membered heteroaryl;
B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituents are selected from the group consisting of:
NRaRb, wherein Ra and Rb are independently H, -(SO2)-NRcRd, wherein Rc and Rd are independently:
H,
Ci-6-alkyl, or -(CO)Ci-6-alkyl;
R1 is Ci-6-alkyl or Ci-6-haloalkyl; R2 is 5 or 6 membered heteroaryl optionally substituted by one, two or three substituents selected from the group consisting of: halogen and Ci-6-haloalkyl; as well as pharmaceutically acceptable salts thereof.
3. The compound of formula (I) according to claim 1 or 2, wherein it is of formula
(Ia):
wherein X, Y, Q, B, R1 and R2 are as described in claim 1 or 2.
4. The compound of formula (Ia) according to claim 3, wherein B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituent is NRaRb, wherein Ra and Rb are both H.
5. The compound of formula (Ia) according to claim 4, wherein they are selected from the group consisting of:
5-{3-[4-(5-Chloro-thiophen-2-yl)-6-trifluoromethyl-pyrimidin-2-yl]-phenyl}- pyridin - 2 -ylamine; 5-{3-[4-(5-Chloro-thiophen-2-yl)-6-trifluoromethyl-pyrimidin-2-yl]-phenyl}- pyrimidin-2-ylamine; and
5-{3-[4-Trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]- phenyl } -pyridin - 2 -ylamine; 5- [3-(6'-Methyl-6-trifluoromethyl- [3,4']bipyridinyl-2'-yl)-phenyl] -pyridin-2- ylamine.
6. The compound of formula (Ia) according to claim 3, wherein B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituent is NRaRb, wherein Ra and Rb are H and -(SO2)-NRcRd, wherein Rc and Rd are independently H, Ci-6-alkyl, or -(CO)Ci-6-alkyl.
7. The compound of formula (Ia) according to claim 6, wherein they are selected from the group consisting of:
3'-[4-Trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]- biphenyl-3-sulfonic acid amide;
5-{3-[4-Trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]- phenyl}-thiophene-2-sulfonic acid amide; 3'- [4-(5-Chloro-thiophen-2-yl)-6-trifluoromethyl-pyrimidin-2-yl] -biphenyl-3- sulfonic acid amide;
5-{3-[4-(5-Chloro-thiophen-2-yl)-6-trifluoromethyl-pyrimidin-2-yl]-phenyl}- thiophene-2-sulfonic acid amide;
3'-[4-Difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]- biphenyl-3-sulfonic acid amide;
5-{3-[4-Difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]- phenyl}-thiophene-2-sulfonic acid amide;
3'-[4-Methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]-biphenyl-3- sulfonic acid amide; 5-{3- [4-Methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl] -phenyl}- thiophene-2-sulfonic acid amide;
3'-(6'-Methyl-6-trifluoromethyl-[3,4']bipyridinyl-2'-yl) -biphenyl-3-sulfonic acid tert-butylamide;
5- [3-(6'-Methyl-6-trifluoromethyl- [3,4']bipyridinyl-2'-yl)-phenyl] -pyridin-2- ylamine;
3'-(6'-Methyl-6-trifluoromethyl-[3,4']bipyridinyl-2'-yl) -biphenyl-3-sulfonic acid amide; and
5- [3-(6'-Methyl-6-trifluoromethyl- [3,4']bipyridinyl-2'-yl)-phenyl] -thiophene-2- sulfonic acid amide.
8. The compound of formula (I) according to claim 1 or 2, wherein it is of formula (Ib):
wherein X, Y, Q, B, R and R are as described in claim 1 or 2.
9. The compound of formula (Ib) according to claim 8, wherein B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituent is NRaRb, wherein Ra and Rb are both H.
10. The compound of formula (Ib) according to claim 9, wherein it is 4- [4- Trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl] - [2,3']bipyridinyl-6'- ylamine.
11. The compound of formula (Ib) according to claim 8, wherein B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituent is NRaRb, wherein Ra and Rb are H and -(SO2)-NRcRd, wherein Rc and Rd are independently H, Ci-6-alkyl, or -(CO)Ci-6-alkyl.
12. The compound of formula (Ib) according to claim 11, wherein they are selected from the group consisting of:
3-{4- [4-Trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl] - pyridin - 2 -yl } -benzenesulfonamide; 5-{4- [4-Trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl] - pyridin-2-yl}-thiophene-2-sulfonic acid amide;
N-Propionyl-3-{4- [4-trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)- pyrimidin-2-yl] -pyridin-2-yl} -benzenesulfonamide;
3-{4- [4-Difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl] - pyridin - 2 -yl } -benzenesulfonamide;
5-{4- [4-Difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl] - pyridin-2-yl}-thiophene-2-sulfonic acid amide;
3-{4- [4-Methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl] -pyridin-2-yl}- benzenesulfonamide; and 5-{4-[4-Methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]-pyridin-2-yl}- thiophene-2-sulfonic acid amide.
13. The compound of formula (I) according to claim 1 or 2, wherein it is of formula
(Ic):
wherein X, Y, Q, B, R1 and R2 are as described in claim 1 or 2.
14. The compound of formula (Ic) according to claim 13, wherein B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituent is NRaRb, wherein Ra and Rb are H and -(SO2)-NRcRd, wherein Rc and Rd are independently H, Ci-6-alkyl, or -(CO)Ci-6-alkyl.
15. The compound of formula (Ic) according to claim 14 wherein they are selected from the group consisting of: N-tert-Butyl-3-{6- [4-methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl] - pyridin - 2 -yl } -benzenesulfonamide;
N-tert-Butyl-3-{6-[4-methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]- pyridin - 2 -yl } -benzenesulfonamide;
3-{6-[4-Methyl-6-(5-trifluoromethyl-pyridin-2-yl)-pyrimidin-2-yl]-pyridin-2-yl}- benzenesulfonamide;
3-{6-[4-Methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]-pyridin-2-yl}- benzenesulfonamide;
N-tert-Butyl-3-(6'-methyl-6"-trifluoromethyl-[2,2';4',3"]terpyridin-6-yl)- benzenesulfonamide; and 3-(6'-Methyl-6"-trifluoromethyl-[2,2';4',3"]terpyridin-6-yl)-benzenesulfonamide.
16. The compound of formula (I) according to claim 1 or 2, wherein it is of formula
(Id):
wherein X, Y, Q, B, R1 and R2 are as described in claim 1 or 2.
17. The compound of formula (Id) according to claim 16, wherein B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituent is NRaR , wherein Ra and R are both H.
18. The compound of formula (Id) according to claim 17, wherein they are selected from the group consisting of:
5-{ l-[4-Trifluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]-lH- imidazol-4-yl}-pyridin-2-ylamine;
5-{ l-[4-Difluoromethyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]-lH- imidazol-4-yl}-pyridin-2-ylamine; and
5-{ l-[4-Methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]-lH-imidazol- 4-yl}-pyridin-2-ylamine.
19. The compound of formula (Id) according to claim 16, wherein B is an optionally substituted aryl or an optionally substituted 5 or 6 membered heteroaryl, wherein the substituent is NRaRb, wherein Ra and Rb are H and -(SO2)-NRcRd, wherein Rc and Rd are independently H, Ci-6-alkyl, or -(CO)Ci-6-alkyl.
20. The compound of formula (Id) according to claim 19 wherein they are selected from the group consisting of:
3-{ l-[4-(5-Chloro-thiophen-2-yl)-6-trifluoromethyl-pyrimidin-2-yl]-lH- imidazol-4-yl}-benzenesulfonamide; and 5-{ l-[4-Methyl-6-(6-trifluoromethyl-pyridin-3-yl)-pyrimidin-2-yl]-lH-imidazol-
4-yl}-pyridin-2-ylamine.
21. A process for the preparation of compounds of formula (I) according to any one of claims 1 to 20 comprising the steps of reacting a compound of formula (X):
with a boronic acid derivative of group B, and a catalyst, to obtain the compound formula
(XV):
wherein A, B, Q, R1 and R2 are as defined in any one of claims 1 to 20.
22. The process according to claim 21 wherein the catalyst is tetrakis(triphenylphosphine) -palladium.
23. A process for the preparation of compounds of formula (I) according to any one of claims 1 to 20 comprising the steps of reacting a compound of formula (XXVI):
(XXVI) with a compound of formula (XXX) : wherein A, B, Q, R1 and R2 are as defined in any one of claims 1 to 20.
24. A compound prepared according to the process of any one of claims 21 to 23.
25. A pharmaceutical composition containing a compound according to any one of claims 1 to 20 for the prevention or the treatment of a disease or condition in which mGluR2 activation plays a role or is implicated.
26. The pharmaceutical composition according to claim 25 wherein the prevention or the treatment of acute and/or chronic neurological disorders such as psychosis, schizophrenia, Alzheimer's disease, cognitive disorders, memory deficits, colon cancer, sleep disorders, disorders of circadian rhythms and glioma.
27. Use of a compound according to any one of claims 1 to 20 for the manufacture of a medicament for the treatment or prevention of a disease or condition in which mGluR2 activation plays a role or is implicated
28. The use according to claim 27 for the treatment and/or prevention of acute and/or chronic neurological disorders comprising psychosis, schizophrenia, Alzheimer's disease, cognitive disorders, memory deficits, colon cancer, sleep disorders, disorders of circadian rhythms and glioma.
29. The invention as hereinbefore described
EP08718155A 2007-04-02 2008-03-25 Pyridine and pyrimidine derivatives as mglur2 antagonists Not-in-force EP2142527B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08718155A EP2142527B1 (en) 2007-04-02 2008-03-25 Pyridine and pyrimidine derivatives as mglur2 antagonists

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07105429 2007-04-02
EP08718155A EP2142527B1 (en) 2007-04-02 2008-03-25 Pyridine and pyrimidine derivatives as mglur2 antagonists
PCT/EP2008/053460 WO2008119689A1 (en) 2007-04-02 2008-03-25 Pyridine and pyrimidine derivatives as mglur2 antagonists

Publications (2)

Publication Number Publication Date
EP2142527A1 true EP2142527A1 (en) 2010-01-13
EP2142527B1 EP2142527B1 (en) 2010-12-29

Family

ID=39457413

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08718155A Not-in-force EP2142527B1 (en) 2007-04-02 2008-03-25 Pyridine and pyrimidine derivatives as mglur2 antagonists

Country Status (17)

Country Link
US (2) US8012986B2 (en)
EP (1) EP2142527B1 (en)
JP (1) JP5303544B2 (en)
KR (1) KR101143152B1 (en)
CN (1) CN101641346B (en)
AR (1) AR065891A1 (en)
AT (1) ATE493400T1 (en)
AU (1) AU2008233956B2 (en)
BR (1) BRPI0809971A2 (en)
CA (1) CA2681733A1 (en)
CL (1) CL2008000936A1 (en)
DE (1) DE602008004236D1 (en)
IL (1) IL200780A (en)
MX (1) MX2009010505A (en)
PE (1) PE20090103A1 (en)
TW (1) TW200845999A (en)
WO (1) WO2008119689A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009203693B2 (en) * 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
US20130137865A1 (en) 2010-08-11 2013-05-30 Taisho Pharmaceutical Co., Ltd. Heteroaryl-pyrazole derivative
JP2014062047A (en) * 2011-01-21 2014-04-10 Taisho Pharmaceutical Co Ltd Pyrazole derivative
WO2013041652A1 (en) * 2011-09-21 2013-03-28 Cellzome Limited Morpholino substituted urea or carbamate derivatives as mtor inhibitors
WO2013119895A1 (en) 2012-02-08 2013-08-15 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
CN104736140A (en) 2012-10-23 2015-06-24 霍夫曼-拉罗奇有限公司 mGlu2/3 antagonists for the treatment of autistic disorders
JP2017513844A (en) 2014-04-23 2017-06-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ MGlu2 / 3 antagonists for the treatment of intellectual disabilities
WO2015191630A1 (en) * 2014-06-10 2015-12-17 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof
MA45795A (en) 2016-07-29 2019-06-05 Sunovion Pharmaceuticals Inc COMPOUNDS AND COMPOSITIONS, AND ASSOCIATED USES
PT3494119T (en) 2016-07-29 2024-12-10 Pgi Drug Discovery Llc Compounds and compositions and uses thereof
CA3070993C (en) 2017-08-02 2025-05-20 Sunovion Pharmaceuticals Inc. Isochroman compounds and uses thereof
KR20210022681A (en) * 2018-06-22 2021-03-03 바이엘 악티엔게젤샤프트 Method for producing tricyclic compound
EP3938045A1 (en) 2019-03-14 2022-01-19 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03007513A (en) * 2001-02-21 2004-07-30 Nps Pharma Inc Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists.
CN100387594C (en) * 2003-04-03 2008-05-14 麦克公司 Diaryl-substituted pyrazole metabotropic glutamate receptor-5 modulators
CA2521399A1 (en) * 2003-04-04 2004-10-21 Merck & Co., Inc. Di-aryl substituted pyrrole modulators of metabotropic glutamate receptor-5
US7442797B2 (en) * 2003-11-04 2008-10-28 Takasago International Corporation Platinum complex and light emitting device
US20060173048A1 (en) 2005-02-03 2006-08-03 Mcarthur Silvia G Imidazole derivatives
WO2007110337A1 (en) 2006-03-29 2007-10-04 F. Hoffmann-La Roche Ag Pyridine and pyrimidine derivatives as mglur2 antagonists
US20070236568A1 (en) 2006-04-11 2007-10-11 Metke Anthony R Method and system for communicating incident scene information

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008119689A1 *

Also Published As

Publication number Publication date
TW200845999A (en) 2008-12-01
ATE493400T1 (en) 2011-01-15
CL2008000936A1 (en) 2008-10-03
KR20090117902A (en) 2009-11-13
AU2008233956B2 (en) 2013-05-02
JP5303544B2 (en) 2013-10-02
US20110263615A1 (en) 2011-10-27
BRPI0809971A2 (en) 2014-10-07
MX2009010505A (en) 2009-10-19
DE602008004236D1 (en) 2011-02-10
CN101641346B (en) 2013-11-06
JP2010524852A (en) 2010-07-22
US8415380B2 (en) 2013-04-09
WO2008119689A1 (en) 2008-10-09
CA2681733A1 (en) 2008-10-09
US8012986B2 (en) 2011-09-06
IL200780A (en) 2013-01-31
KR101143152B1 (en) 2012-05-08
EP2142527B1 (en) 2010-12-29
PE20090103A1 (en) 2009-02-13
CN101641346A (en) 2010-02-03
AU2008233956A1 (en) 2008-10-09
AR065891A1 (en) 2009-07-08
IL200780A0 (en) 2010-05-17
US20080280924A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
EP2142527B1 (en) Pyridine and pyrimidine derivatives as mglur2 antagonists
KR101156897B1 (en) Pyridine and pyrimidine derivatives as mglur2 antagonists
TWI436993B (en) Acetylene derivative
AU2014300673A1 (en) Heteroaromatic compounds and their use as dopamine D1 ligands
EP1027336A1 (en) Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors
EP2513102B1 (en) Ethynyl derivatives
NZ541643A (en) Imidazol-4-yl-ethynyl-pyridine derivatives
KR101576343B1 (en) Pyrazolidin-3-one derivatives
ES2355693T3 (en) DERIVATIVES OF PIRIDINE AND PYRIMIDINE AS ANTAGONISTS OF mGluR2.
NZ614883B2 (en) Pyrazolidin-3-one derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091102

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602008004236

Country of ref document: DE

Date of ref document: 20110210

Kind code of ref document: P

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602008004236

Country of ref document: DE

Effective date: 20110210

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2355693

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20110330

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E009852

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20101229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110329

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110329

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110330

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110429

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110429

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110331

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20110930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602008004236

Country of ref document: DE

Effective date: 20110930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110325

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101229

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20150226

Year of fee payment: 8

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20160314

Year of fee payment: 9

Ref country code: ES

Payment date: 20160310

Year of fee payment: 9

Ref country code: NL

Payment date: 20160307

Year of fee payment: 9

Ref country code: CH

Payment date: 20160125

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: HU

Payment date: 20160225

Year of fee payment: 9

Ref country code: SE

Payment date: 20160307

Year of fee payment: 9

Ref country code: BE

Payment date: 20160315

Year of fee payment: 9

Ref country code: AT

Payment date: 20160224

Year of fee payment: 9

Ref country code: FI

Payment date: 20160311

Year of fee payment: 9

Ref country code: FR

Payment date: 20160223

Year of fee payment: 9

Ref country code: GB

Payment date: 20160224

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20160324

Year of fee payment: 9

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602008004236

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170325

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20170401

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 493400

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170325

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20170325

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170326

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20171130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171003

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170401

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170331

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170326

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170325

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170331

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170325

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170331

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170325

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170325

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20170331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170331

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20180704

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170326